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ABSTRACT 
 
 
Diane Elizabether Bender: Characterization of a Feline Model of Factor XII 
Deficiency: The In Vivo Role of FXII in Vascular Injury and Inflammatory Responses 
(Under the direction of Dwight A. Bellinger, D.V.M, Ph.D) 
 
 
For nearly 6 decades scientists have been identifying and defining the many 
roles of the blood serine protease Factor XII (FXII) in vitro and in vivo.  Each year we 
gain new information about this elusive protein, however conflicts still exist over the 
importance of FXII in human disease states. Factor XII participates in coagulation, 
fibrinolysis, renin-angiotensin, and immune system responses making it an integral 
part of mammalian life.  Animal models offer the best way to study the importance of 
a factor in vivo, however only two readily available FXII deficient models exist, i.e. 
the gene-manipulated mouse and our cats.  This work characterizes the origin of the 
genetic defect causing FXII deficiency in a colony of domestic cats, and investigates 
in vivo acute responses to intravascular and intradermal (extravascular) injury.  
Ultimately we aim to provide a well defined animal model for therapeutic targeting 
 iv 
strategies, and gain new insights into the importance of FXII in cellular and 
extracellular interactions. 
Chapter 1 provides a comprehensive overview of the biological features of 
FXII: its importance as a central player in coagulation, fibrinolysis, complement 
activation, the innate immune system, and vascular repair; its molecular and genetic 
structure and cellular interactions; and the attributed pathophysiology derived from 
human and mouse studies.   Chapter 2 details the feline FXII gene and the mutation 
discovered in our colony along with protein studies to confirm our findings.   
Vascular injury and associated fibrinolytic and inflammatory response studies 
comprise Chapter 3.  We found that FXII procoagulant activity is not necessary to 
initiate clotting and to form stable thrombi upon an initial venous or arterial injury.  
However, FXII appears to aid in clot stability following a second intravascular injury 
48 hours later on the contralateral veins.  Inflammatory mediators are also 
significantly reduced in FXII deficient animals.  Chapter 4 addresses the role of FXII 
in recruiting inflammatory cells to a site of heme-induced skin injury.  Our studies 
explore a new method of nitric-oxide driven innate immune response, finding 
significantly fewer inflammatory cell infiltrates in FXII deficient cats.  Chapter 5 
offers future studies to pursue with this model based on results of these dissertation 
findings. 
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BACKGROUND AND SIGNIFICANCE 
 
Vascular Thrombosis: Incidence and Impact 
 
Each year in the United States of America nearly 700,000 people suffer a 
fatal thrombotic event.1 An additional 200-600,000 people are diagnosed and undergo 
treatment for an intravascular thrombus, making vascular thrombosis the leading 
cause of mortality and morbidity.1,2 Today’s therapeutic strategies for thrombolysis 
and thrombus removal can be effective but they carry risks of their own.  We need 
greater knowledge of the mechanisms and risk factors associated with thrombophilia 
so we can develop safer therapies and earlier interventions.  We need better public 
awareness of thrombosis and it’s symptoms in order to combat this major disease.  
FXII in Coagulation: History and Controversy 
Concepts in hemostasis and thrombosis are still emerging.  Lipids, 
lipoproteins, coagulation proteins, cell membrane receptor proteins, and other soluble 
factors interact in a perfectly orchestrated manner under specific conditions to form a 
blood clot.  Unfortunately scientists today have limited understanding of how these 
elements specifically interact.  One factor still shrouded in mystery is the blood serine 
 2 
protease, factor XII or Hageman factor named after the first patient diagnosed with its 
deficiency.  In 1955, Drs. Ratnoff and Colopy described a patient, Mr. John 
Hageman, who presented with a prolonged test tube clotting time yet suffered no 
bleeding tendencies.3 They concluded Mr. Hageman lacked a blood protein that 
initiated clotting in a glass test tube.  Ratnoff and colleagues further established that 
coagulation factors circulate as inactive precursors until becoming activated in the 
blood. Factor XII’s activation upon contact with a negatively charged surface was 
termed ‘autoactivation’ and further initiated a sequence of proteolysis in a proposed 
cascading manner thereby giving it the name ‘contact activator’ of the intrinsic 
pathway of coagulation.4 Since Mr. Hageman was able to form intravascular blood 
clots (and eventually died of a pulmonary embolism), FXII was thought to be of 
minor importance in vivo because some other factor(s) could act in its absence.  After 
the index patient was reported, a few additional FXII deficient (or Hageman trait) 
people and animals were identified.  Many of these deficient humans appeared to 
have a thrombotic tendency i.e. thrombophilia, however it was unclear if FXII alone 
or in combination with other risk factors was the cause of their disease.  Various 
clinical investigations have looked at the impact of FXII on cardiovascular disease, 
venous thrombosis and pregnancy/fetal loss, however the results have been mixed and 
controversy still exists.  From the 1960s through today, researchers defined many of 
the in vitro characteristics of FXII from humans and other species. The in vivo 
importance of FXII in hemostasis, pathological thrombus formation and other 
biological pathways has been difficult to study due to low numbers of Hageman trait 
persons and different findings in FXII deficient animal models of mice and cats. 
 3 
The incidence of congenital FXII deficiency in human and domestic feline 
populations appears to be low.  Factor XII deficiency is generally an inherited 
autosomal-recessive trait in humans and cats with an incidence of 1-5%.5-7  Small 
studies in Asian populations report an incidence of mild and severe FXII deficiency 
as high as 10%.8 This higher rate could be attributed to assay reagent differences and 
to a FXII gene mutation frequency.8,9  Most of the population incidence and 
thrombotic risk studies have focused on families and individuals of German, Spanish, 
Italian, and Swiss ethnicity who carry a congenital abnormality.  Acquired FXII 
inhibitors have also been identified in patients with anti-phospholipid syndrome 
(APS), metastatic cancer, and liver disease.10-12 Acquired FXII inhibitors are 
generally antibodies directed against FXII. 
Controversy about the role of FXII in thrombotic events and pregnancy loss 
continues to be a topic of research and speculation.  Early reports of severe FXII 
deficient individuals (having less than 1% procoagulant activity determined by an 
activated partial thromboplastin time or APTT) indicated a possible association with 
the risk of developing a venous thrombus.  Seven out of eleven cases reported from 
1968 through 1990 had some other risk factor known to predispose someone to 
venous thrombosis, such as pregnancy, Factor V Leiden or antithrombin mutation, 
traumatic injury, or sepsis.13 The four other cases had no information about associated 
risk factors or family history of the individuals reported.  Girolami et al. argue that 
concluding an association of prothrombitic risk and low levels of FXII is unjustified 
even in arterial thromboses such as myocardial infarctions since they have followed 
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21 severely deficient patients and 58 patients moderately deficient in FXII for 16 
years and only 1 patient developed a heart attack.14  Other large studies of coronary 
heart disease (CHD) and myocardial infarction (MI) have reported conflicting results 
concerning the impact of FXII levels on disease outcome and risk. A study of 2464 
middle aged men who had at least one previous MI  found a statistically significant, 
independent, and positive association of FXIIa with other CHD risk factors of serum 
cholesterol and triglyceride concentrations, blood pressure, body mass index, factor 
VII activity, plasma fibrinogen concentration, and tobacco smoking.15  Another study 
examining survivors of myocardial infarction found FXIIa levels positively correlated 
with factor VII coagulant activity, body mass index, cholesterol, insulin, plasminogen 
activator inhibitor-1 (PAI-1) antigen, tissue plasminogen activator (tPA) antigen and 
triglycerides.  Factor XIIa levels were associated strongly with the extent of coronary 
stenosis.  The data suggests that the high levels of FXIIa could be a marker of 
increased coagulability in these patients and it could represent a persistent 
hypercoagulable state for further coronary thrombosis.16  In contrast, a coronary 
prevention study of Scottish men with high cholesterol showed an association of a 
common FXII gene mutation (resulting in lower levels of circulating FXII) with a 
higher risk of developing CHD.17  Factor XIIa levels may reflect contact activation 
induced by higher levels of lipids (see next section on Serine Proteases Activation) or 
inactivated FXIIa bound to an inhibitor yet still detectable with an antibody.  Lower 
FXIIa levels could indicate a loss of fibrinolytic activity (see section on FXII In 
Fibrinolysis) resulting in enhanced thrombus retention in the vessel.  Other studies 
agree with one outcome or the other, leaving it unclear if FXII should be considered a 
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marker of atherosclerotic vascular damage18, an independent risk factor for CHD19, or 
just a consequence of a thrombotic disease state.20 
The question of FXII’s importance in pregnancy retention or fetal loss is 
also under debate.  In the early 1990s FXII levels were evaluated during pregnancy 
and found to increase during the last trimester.21  Fertility researchers and clinicians 
began to report cases in which patients with low levels of FXII had multiple 
spontaneous abortions before the third trimester.22,23  Some of these cases may have 
underlying thrombophilic risk factors such as Factor V Leiden mutation, 
autoantibodies to phosphatidylethanolamine (aPE), or anti-phospholipid syndrome 
(APS) that are associated with pregnancy loss.24,25  Again, the associations of low 
FXII levels with pregnancy complications were contradicted by findings of no 
increased pregnancy losses or thrombotic events in severely FXII deficient women.26  
Animal models of FXII deficiency have addressed these questions of thrombosis and 
pregnancy outcomes.  In 2004, Pauer et al. generated a mouse model by targeted 
deletion of the FXII gene (referred to as FXII -/- for homozygous gene deletion) that 
has no FXII transcript nor protein production.27 When male FXII -/- and female FXII 
-/- mice were mated, litter sizes were the same as related normal (referred to as wild-
type or FXII +/+) mice from the same genetic backgrounds. They also found no 
thrombophilia in the FXII deficient mice.27 The mouse model of FXII deficiency 
indicates there is no association of FXII with fetal loss or increased thrombotic 
tendencies.  The feline model of congenital FXII deficiency is currently being studied 
for fetal loss.  Preliminary observations suggest there might be an association of low 
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levels of FXII with fewer kittens born (unpublished data) however issues of genetic 
background and breeding environment need to be addressed before any conclusions 
can be drawn.  More direct assessment of FXII’s in vivo role during pregnancy is 
needed to settle this controversy. 
The mouse FXII deficient model was created to clarify the discrepancies 
between studies of humans with Hageman trait, however new conflicts have arisen.  
Vascular injury studies on aortas and carotid arteries indicate FXII-/- mice form 
reduced size thrombi that are less stable at sites of attachment to the vasculature. 
Further studies with FXII-/- mice suggested that thrombin-induced activated platelets 
may promote thrombus formation in a FXII-dependent way.28 These animal studies 
and others confirmed that FXII is not necessary for hemostasis, but opened new 
discussions about the role of FXII in pathological thrombus formation (see next 
section for more details) and mouse coagulation.29  Factor XII deficiency may have a 
protective effect by forming smaller, looser thrombi, however these thrombi could 
break away and form pathological thrombi elsewhere.  The vascular injury studies 
presented in this dissertation continue the discussions and add new conflicting data 
about the in vivo role of FXII.  
Serine Proteases Structure, Function, and Activation in Contact 
Activation 
 
Nearly all the proteins involved in blood coagulation and complement 
activation are serine proteases.  Serine proteases are enzymes that cleave specific 
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peptides and have at least one serine amino acid residue in their active site. Serine 
proteases are grouped into families and clans according to structural similarities or 
homologies and sequence similarities based on their catalytic domain 
characteristics.30 Most serine proteases are secreted as inactive precursors or 
zymogens which require proteolysis to become active and capable of hydrolyzing 
peptide bonds of their target protein. Cardinal features of serine proteases are the 
formation of an oxyanion hole after zymogen activation, the conserved geometrical 
location of a nucleophilic Serine (Ser) adjacent to a histidine (His) in the catalytic 
site, and a buried ‘proton accepting’ aspartate (Asp) in the catalytic apparatus.30 The 
Ser-His-Asp formation is referred to as the ‘catalytic triad’ and provides for strong 
hydrogen bonding between His-Asp and proton transferring between the non-
covalently bound substrate and active site residues. Coagulation and fibrinolytic 
proteases have inhibitors (serine protease inhibitors or serpins) that prevent their 
activation and limit the clotting or fibrinolytic process—a way to maintain 
homeostasis.  Factor XII is a serine protease that has multiple inhibitors: Complement 
1 inhibitor (C1-INH), antithrombin III (ATIII), alpha-2-antiplasmin, and the non-
serpin inhibitor alpha-2-macroglobulin.31,32 Complement 1 inhibitor is the major 
plasma inhibitor of FXII and its substrate kallikrein.32 Factor XII can be 
‘autoactivated’ via a conformational change when it contacts certain surfaces, hence it 
is called a contact activation factor.4,33 Previous thinking was that FXII zymogen 
became activated to FXIIa when it contacted anionic ‘negatively charged’ hydrophilic 
surfaces.  New evidence shows spontaneous activation of FXII occurs upon contact 
with anionic surfaces, however FXIIa production can occur when the zymogen is 
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putatively adsorbed to a hydrophobic (water repelling) surface then displaced by 
some other protein.33 Furthermore, the manner of zymogen adsorbing to a surface 
(transiently vs. directly) can influence whether the kallikrein-kinin or coagulation 
pathway is activated by FXIIa.34 Over the years, various FXII-activating substances 
have been identified: glass, polyethylene, silicone rubber, metals, kaolin, ellagic acid, 
dextran sulfate, sulphatides, endothelial cell-associated glycosaminoglycans, 
polyphosphates, phospholipids, sodium urate crystals, free nucleic acids, aggregated 
amyloid peptides, articular cartilage, heparins, bacterial endotoxins, misfolded 
proteins, type I collagen and many other agents. 4,33,34  Recently it was reported that 
aggregates of misfolded proteins (often found in inflammatory diseases) could 
activate FXII without initiating the coagulation cascade protease target factor XI 
(FXI)34, while type I collagen also activates FXII35.  This new information about 
physiologically relevant activators has sparked new interest in the role of FXII in 
inflammation (to be discussed later).   
Coagulation is the process in which blood serine proteases activate each 
other to form a clot (thrombus).  The thrombus is composed of a network of 
polymerized fibrin, platelets, and blood cells that associate in a way that allows 
immediate reduction or stoppage of fluid flow yet can be lysed at a later time.  A 
delicate balance between hemostasis and thrombosis is provided by complex protein 
interactions, feedback activation mechanisms, and specific proteolytic inhibitors.  
When a vessel is injured, the  blood cells, platelets, endothelial cells, pericytes and 
surrounding matrix provide substances that are thrombogenic i.e. they promote clot 
 9 
formation by the intrinsic (contact activation factors plus factor IX and VIII) and 
extrinsic (tissue factor required) coagulation pathways.36-38 The two pathways are not 
exclusive of each other: Tissue factor expressed on perturbed pericytes/adventitial 
cells and monocytes or released from platelets, leukocytes, and endothelial cells in the 
form of microparticles (MP) binds with factor VIIa to activate the intrinsic pathway at 
factor IX (FIX) and the extrinsic pathway at factor X (FX).  The pathways converge 
into a “common” pathway (at factor Xa) which continues the proteolytic cascade until 
the final target, fibrinogen, is activated to fibrin by thrombin.29,36-38 Figure 1.1 
illustrates the interactions of the pathways.  Factor IXa requires a cofactor, factor VIII 
(FVIII), and phospholipids in order to convert FX to FXa. Absence of FVIII or FIX 
results in the bleeding disorders hemophilia A or B, respectively.36 In hemophiliac 
patients, clotting can be induced by giving them supraphysiological doses of factor 
VIIa (FVIIa), a serine protease that complexes with TF to initiate the extrinsic 
pathway.36 Factor X and its ability to complex with factor V (FV) and phospholipids 
to form the “prothrombinase” complex is critical for activating small amounts of 
thrombin. Thrombin (FIIa) is a serine protease that acts on multiple substrates 
including fibrinogen, factor XIII (fibrin stabilizing factor), FV, FVIII, and FXI, and 
glycoprotein V on platelet surfaces.  The positive feedback action induced by trace 
amounts of thrombin generated during extrinsic pathway activation helps to 
accelerate thrombin production and create a “burst” of thrombin at the injury site.36 
Thrombin is a crucial element of clotting, therefore most anticoagulant therapies 
target or involve thrombin inhibition. The main plasma inhibitors of thrombin are 
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antithrombin III, heparin (in complex with antithrombin III), protein C inhibitor 
(PCI), and plasminogen activator inhibitor-1. 
 In vivo coagulation begins with the adherence and spreading of platelets to 
the damaged endothelial cells, followed by a secondary phase mostly initiated by the 
extrinsic pathway via tissue factor (TF) either bound to a membrane or blood-borne. 
35-38
 In vitro coagulation is initiated by FXII directly adsorbing to a surface of glass or 
polystyrene.33,36-38 In humans and animals, the loss of contact activation factors FXII, 
prekallikrein (PK), and high molecular weight kininogen (HK) does not result in a 
bleeding tendency, thus the intrinsic coagulation pathway provides an alternate way 
to generate more thrombin.35,36,38  Ex vivo studies have shown that the amount and 
rate of thrombin activation may determine the strength and stability of the clot 
formed.39-41 When the large hexameric glycoprotein fibrinogen is cleaved by 
thrombin, the Aα and Bβ chains of fibrinogen lose their N-termini and “half-
staggered, double-stranded protofibrils [form] followed by thickening of protofibril 
chains”.39  The double-stranded protofibrils interact laterally to form long thin 
strands/fibers and eventually polymer chains then networks.36  Factor XIII (with 
calcium) is activated by thrombin, induces cross-linking of the fibrin polymers, and 
confers stability i.e. resistance to plasmin degradation.36,39 Clots formed in vitro by 
contact activation/FXIa40 or under higher concentrations of thrombin41 are composed 
of thinner fibers and are more stable and recalcitrant to lysis. Since fibrin is a 
substrate and a cofactor for the main fibrinolytic protease plasmin, its availability for 
interacting with plasmin can influence the rate of clot lysis.39 Thin fibrin fibers 
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generate plasmin at a reduced rate42 by possibly limiting the access of plasminogen 
activators or by increasing an inhibitor of fibrinolysis. Clots containing loosely 
assembled, thicker fibrin fibers are easier to lyse and can be generated by TF-
FVIIa/Xa initiated coagulation.40 New evidence that collagen can activate FXII and 
activate platelets at their immunoglobulin receptor glycoprotein VI (GPVI) suggests 
an “initial” appearance of the contact activation pathway is seen in vivo during the 
primary phase of hemostasis.35  The early activation of FXII can provide a way to 
generate coagulation factors (i.e. thrombin) at the attached platelet surface and help 
strengthen and stabilize the clot. These intriguing findings suggest that driving a 
coagulation pathway toward an extrinsic activation method could affect clot structure 
and stability which may be important in pathological outcomes.  The contact 
activation pathway may be more important than previously thought. 
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Figure 1.1: Coagulation Pathways 
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Contact activation factors connect hemostasis with other biologically 
important pathways such as kallikrein-kinin, complement activation, fibrinolysis, and 
extracellular remodeling.  Activated FXII or prolylycarboxypeptidase cleave the 
zymogen prekallikrein to kallikrein thereby initiating the plasma kallikrein-kinin 
system (KKS).32 Plasma and tissue kallikreins are serine proteases that cleave 
prourokinase, prorenin, FXII, and HK (further cleaves into bradykinin).36 Kallikrein‘s 
activation of FXII generates a positive feedback regulatory mechanism to amplify the 
contact activation pathway in plasma and on the surface of endothelial cells. 
Prekallikrein reversibly binds to the surface of neutrophils, platelets, endothelial cells 
 13 
and matrix and can activate HK in its membrane-bound receptor complex.  Kallikrein 
activates a second plasminogen activator, prourokinase (single chain uPA) to 
urokinase (uPA) on the endothelial cell—initiating fibrinolysis at the cell/vessel 
surface.32,36 High molecular weight kininogen is a cofactor/substrate that forms a 
complex with globular complement C1q receptor (gC1qR), urokinase plasminogen 
activator receptor (uPAR), cytokeratin 1 (CK1), and prolylycarboxypeptidase 
(PRCP).32,36 This complex of HK-gC1qR-uPAR-CK1 can serve as a template on 
endothelial cell surfaces to bind and activate FXII, or in the absence of FXII it can 
activate PK (if PRCP is present).32 High molecular weight kininogen also serves as a 
bridge for neutrophil binding to platelets at the glycoprotein Ibα-V-IX complex.43  
Activated HK (HKa) has anti-adhesive and apoptotic properties attributed to its 
interactions with extracellular matrix proteins (ECM).44 Activated HK is also 
important in liberating bradykinin (a nonpeptide hormone) which is a potent activator 
of tissue-type plasminogen activator (tPA), and releasing agent of nitric oxide (NO) 
and prostacyclin from endothelial cells.32,45  Bradykinin reduces/regulates blood 
pressure (as an endogenous vasodilator), causes capillary leakage and edema (and 
pain), inhibits platelet responses, and stimulates intimal hypertrophy and smooth 
muscle cell proliferation after vascular damage.46  Over generation of bradykinin 
impacts inflammatory diseases such as hereditary angio-edema, vasculitis, ulcerative 
colitis, arthritis, and encephalomyelitis.46-48 Since the KKS is important in 
inflammation, fibrinolysis, and vascular remodeling, its modulation is important in 
many diseases. The multiple pathway interactions of the contact activation system are 
shown in Figure 1.2. 
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Factor XII has a more pivotal role in vivo because it can directly activate 
complement, plasminogen (fibrinolysis target), leukocytes, and extracellular matrix 
metalloproteinases (remodeling enzymes) in addition to its indirect actions via the 
KKS.  Each of these interactions will be discussed in depth in the subsequent 
sections.       Figure 1.2: FXII/Contact Activation In Multiple Pathways 
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FXII Domain Structures: Analyses and Implications They Carry 
Human FXII protein exists as a ~80,000 Daltons (~80 kDa) zymogen in the 
blood until being activated by surfaces, kallikrein, plasminogen (PLG), or itself.  
Activation of FXII at the arginine (Arg)353-valine (Val)354 (a newer numbering system 
lists it as Arg373-Val374 however I will use the traditional nomenclature) bond results 
in two main products FXIIa and FXII fragment (FXIIf or β-FXIIa, ~30 kDa).49 Factor 
XIIa is a two-chain molecule (~80 kDa) having a heavy chain (353 residues, ~52 
kDa) and a catalytically active light chain (243 residues, ~28 kDa) held together by a 
disulfide bond.  Factor XIIa is further hydrolyzed by kallikrein at the Arg334-Asn335 
and Arg343-leucine (Leu)344 residues into products lacking the heavy chain, therefore 
it cannot bind surfaces and activate FXI.  The two β-FXIIa products retain the 
catalytic triad active region allowing them to cleave some zymogens such as PK, but 
they differ in structure by being disulfide linked to either a 10- or 19-amino acid 
residue carboxyl-terminal end.49 Computer-modeling suggests β-FXIIa shares a 3-
dimensional structural homology to pancreatic serine proteases, but little is known 
about its function(s).50  
  The light chain of FXIIa is the serine protease portion of the molecule and 
homologous to tPA, with the highest homology occurring at the catalytic triad region 
(His393, Asp442, Ser544).49,50  The light chain comprises Val354-Ser596 amino acid 
residues and contains one amino-linked carbohydrate chain on Asn414.49 Plasma 
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activity of the light chain is fully expressed when binding of the heavy chain to a 
surface, HK, and kallikrein or FXI are all contiguous.49 Bound two-chain FXIIa can 
hydrolyze the substrates FXI or PK which are noncovalently associated with HK in 
the plasma. Zinc accelerates the autoactivation and hydrolysis by kallikrein.51 The 
main inhibitor of FXIIa, C1-INH, reversibly binds in the exposed reactive site by 
presenting a peptidyl bond (P1-P1’) that matches the P1(Arg) –P1’(Threonine) of its 
substrate (FXIIa).52  Specificity of the inhibitor binding is determined by the P1 
residue of the substrate—Arg353 for FXIIa. 
The heavy chain of FXIIa has multiple structural domains of which little is 
known about their specific function.  The human FXII heavy chain amino acid 
structure was first reported53 and confirmed54 for the predicted primary structure in 
1985 however no three-dimensional structure has been reported to date.  The heavy 
chain comprises isoleucine (Ile)1 through Arg353.  Amino acids Ile1 through Cys28 on 
the amino-terminus (N-terminus) bind platelets at the glycoprotein Ibα-IX-V complex 
and are part of the ~60 residue region (Lys13-Cys69) that shares homology with the 
type II region of fibronectin.49,55  This type II fibronectin-like domain is predicted to 
be a collagen binding region where  FXII putatively binds anionic surfaces56 and the 
HK-gC1qR-uPAR-cytokeratin 1 complex on endothelial cells57 (at FXII residues 
Tyr39-Arg47).  The next secondary structural domains are two epidermal growth 
factor-like domains (residues Cys79-Cys111 and Cys159-Cys190) and a type I 
fibronectin-like domain. Epidermal growth factor-like domains are found in many 
proteins including transforming growth factor type 1, tPA, factor IX, and several 
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coagulation proteins.49  The epidermal growth factor domains in FXII may be regions 
of neutrophil and monocyte binding.49,58  Factor XII residues Cys116-Cys144 comprise 
the “finger shaped” type I fibronectin-like domain that are thought to be important in 
binding fibrinogen, heparin, amyloid, and ECM proteins fibronectin and 
vitronectin.49,54,59,60 The remaining amino acid residues of the FXIIa heavy chain form 
a kringle domain (Cys198-Cys276) and a proline-rich region (proline (Pro)313-Arg334 
and Leu344-Arg353).  The kringle domain function in FXII is unclear but suspected to 
participate in binding fibrinogen and fibrin. Multiple kringle domains have been 
found in prothrombin, plasminogen, urokinase (uPA), and tPA.49 The proline-rich 
region participates in artificial surface binding61 and perhaps other unknown 
functions.  
FXII In Fibrinolysis 
Fibrinolysis (also called thrombolysis) is the break-down or degradation of a 
fibrin clot into fibrin degradation products (FDPs) by a variety of enzymes.  The 
fibrin clot is actually a mixture of plasminogen, thrombin, and other hemostasis 
proteins bound to fibrinogen and fibrin strands.  Fibrin can regulate its own 
degradation by binding plasminogen and its activator tPA to its surface.62 In the 
presence of fibrin, tPA’s catalytic activity is increased by more than 2 orders of 
magnitude.  The main enzyme that initiates the fibrinolytic process is the serine 
protease plasmin, derived from the zymogen plasminogen.  Plasminogen binds to 
fibrin through kringle domains and can be activated to plasmin by tPA, uPA, FXIIa, 
and possibly unknown proteases.62 As plasmin cleaves fibrin, soluble degradation 
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products are formed and carboxy-terminal lysine residues are exposed. The kringle 
domains of tPA and plasminogen contain lysine-binding sites to aid in fibrin binding 
and enhance degradation. The thrombin-activatable fibrinolysis inhibitor (TAFI) can 
remove carboxy-terminal lysine residues, thereby inhibiting plasmin generation and 
fibrinolysis.62 Plasmin has two main endogenous inhibitors: alpha-2-antiplasmin and 
alpha-2-macroglobulin.  When plasmin is bound to fibrin, alpha-2-antiplasmin cannot 
bind to plasmin. However, TAFI can remove the lysine residues that would bind 
plasminogen thereby attenuating fibrinolysis. The activation of plasminogen is 
controlled by the fast-acting plasma protease inhibitors plasminogen activator 
inhibitor-1 and -2 (PAI-1 and PAI-2), C1-INH, and the broadly specific alpha-2-
macroglobulin. Plasminogen activator inhibitor-2 is found in high levels only during 
pregnancy, thus not normally a significant serpin. Almost immediately upon 
secretion, tPA and uPA bind to PAI-1 which is secreted by endothelial cells, 
macrophages, monocytes, adipocytes, and platelets. The tPA-PAI-1 complex is 
stabilized by matrix proteins (primarily vitronectin).63 Tissue plasminogen activator 
and uPA are secreted as “less active” single chain molecules by endothelial cells, but 
uPA is also expressed on macrophages and renal epithelial cells. The single chain-
uPA is cleaved to a high and a low molecular weight fragment, but only the high 
molecular weight can bind to uPA-receptor on endothelial cells, monocytes, 
macrophages, fibroblasts.62 The function of the uPAR is still unclear, but it is thought 
to be important in regulating cell adhesion and cell signaling.64 Most of the 
fibrinolytic activity of plasma is attributed to tPA, whereas uPA appears to be more 
active in tissues.  
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Currently very little is known about FXII’s participation in fibrinolysis, with 
most of our knowledge being gained through in vitro assays. Braat et al. published the 
most extensive evaluation and quantification of FXII as a plasminogen activator.65 
Their studies used a purified system and dextran sulfate-activated human plasma 
euglobulin fractions that were evaluated in a fibrin clot microtiter plate assay.  The 
euglobulin fraction is formed by precipitation of plasma proteins and collection of the 
precipitate.  Kluft determined that a large amount of C1-INH and other inhibitors 
were also precipitated in the euglobulin fraction, and altering the ionic strength or pH 
could influence their amounts.66 Activating the plasma with dextran sulfate (an 
activator of FXII), altering the pH, and adding flufenamate (inhibits C1-INH and 
alpha-2-antiplasmin) yields the highest level of fibrinolytic activity that is contact 
activation factor dependent.65,67,68 Braat et al. tested purified FXII activated with 
dextran sulfate in buffer and found low levels of plasminogen activator (PA) activity.  
However, dextran sulfate added to plasma (dextran sulfate euglobulin fraction or 
DEF) and blocking of tPA and uPA activity resulted in a 6 fold increase in PA 
activity.  The direct contribution of FXIIa as a PA in normal plasma was determined 
to be about 12% (or 20% of contact activation-dependent PA activity).65 Earlier 
studies by Kluft et al. and Levi et al. determined contact activation factor contribution 
was 50%69, however FXII may only contribute half of that or ~25% (tPA contributes 
50% overall, uPA contributes 25% overall).70 It appears FXII can provide 12-25% of 
the fibrinolytic activity in plasma. 
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Persons with severe FXII deficiency have been reported to have low plasma 
(euglobulin fraction) fibrinolytic activity related to FXII plasminogen activation.70-72  
Speculation has been made that FXII deficient individuals may be prone to 
pathological thrombus formation (attributed to reduced fibrinolytic ability), yet no 
clear evidences have been found.  In vivo animal studies using FXII deficient subjects 
have not fully addressed this question. 
FXII In Inflammation 
Inflammation is a multi-step process that occurs as a response to injury or 
infection in vascularized tissues.  Serine proteases, such as FXII and kallikrein, play a 
pivotal role in initiating primary response elements necessary for host defense and 
homeostasis after an injury.  Factor XII is particularly interesting because it has the 
power to activate four systems involved in the inflammatory process: kallikrein-kinin, 
clotting, fibrinolytic, and complement.  Each of these systems have a cascading effect 
on other systems through the production of chemical mediators acting to recruit 
cellular responders (e.g. leukocytes, fibroblasts, smooth muscle cells, endothelial 
cells) while maintaining primary host defenses (e.g. bacterial removal) and 
hemostasis.  
For over 50 years the contact activation system’s involvement in 
inflammation has been studied, however mostly in a venue of in vitro, manipulated 
environments using  Boyden chemotaxis chambers, microcapillary flow chambers, 
and cell or tissue culture methods.  Factor XIIa can directly bind to immune cells and 
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endothelial cells73.  Neutrophils (PMNs) have been shown to directly bind fibrin and 
FXIIa through the Mac-1 or CD11b/CD18 receptor via the protease-mediated 
pathways of cathepsin G and elastase stored in their azurophil granules.74,75 Upon 
binding FXIIa, the PMNs can release the contents of the granules to aid in degrading 
bacteria, collagen, elastin, and other proteoglycans.  Degradation products of collagen 
are chemotactic for PMNs, monocytes, and fibroblasts.  Macrophages (or tissue 
monocytes) are important in host defense against bacteria and clearing 
immunoglobulin (Ig)-coated cells or Ig-complexes that bind to the macrophage Fc 
gamma receptor I (FcγRI).  Factor XIIa can reduce the number of FcγRI ligand 
binding sites on macrophages by 80%.58   Reduced efficiency of FcγRI-IgG 
interactions can compromise the clearance of Ig complexes and exacerbate an 
inflammatory response.76 Factor XII has been shown to bind platelets at their 
glycoprotein Ibα (GPIbα) receptor, the receptor where HK can act as a bridge for 
PMN-surface-adherent platelet interactions.77 The binding of FXII to the GPIbα 
receptor can inhibit thrombin binding and platelet aggregation78, suggesting FXII may 
be important in homeostatic regulation of leukocyte-platelet interactions on the 
endothelium.   
Factor XII can indirectly effect inflammatory reactions by inducing 
chemokines, activating complement, and liberating bradykinin.  Early studies in 
FXII-deficient humans79,80 and cats81 found skin reactions to FXII activators or 
complement activators resulted in significantly less local inflammation. The results of 
these experiments suggested the complement system and/or the KKS were not 
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effectively activated in the absence of FXII. Recently Zabel et al. found FXIIa is a 
potent activator of the serum chemoattractant chemerin which is known to activate 
dendritic cells and macrophages.82 
Factor XIIa has been shown to activate complement protein C1qr2s2 to C1s 
and C1r83, the first components of a “classical” complement protease cascade in 
which products C3a, C4a, and C5a serve as chemoattractants, platelet activators, and 
lysis-inducing agents of pathogens and cells.84 Complement activation generates a 
proinflammatory response by the body that is primarily controlled by C1-INH—
giving this serpin multiple biological properties also. 
 Very little research has addressed the importance of FXII in leukocyte 
chemotaxis as a result of vascular injury.  Thrombus development is an inflammatory 
process involving chemokine and cytokine driven cellular responses to the site of 
vessel injury.  Various groups have looked at monocyte85, neutrophil86-88, and mast 
cell89 recruitment to the thrombus and have defined certain inflammatory mediators 
are important in thrombus development and resolution. Most of this research has 
focused on chemokine, cytokine, and matrix metalloproteases roles in vascular 
inflammation without addressing contact activation factors participation in this 
process.   
FXII and Matrix Metalloproteinases In The Wound Repair and Remodeling Process 
 
 
Besides a role for FXII in the initial inflammatory responses to injury, FXII 
may also play a role in proliferation of tissue by activating matrix metalloproteinases.  
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Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases capable of 
degrading all types of matrix proteins (such as basement membrane, collagens, 
proteoglycans, fibronectin, laminin) and plasma proteins such as fibrinogen and 
FXII.90 The MMPs are synthesized as zymogens then secreted or membrane-bound 
until catalyzed to their active form.  Fibroblasts, smooth muscle cells91, 
monocytes/macrophages92, NK cells93, and neutrophils94 are reported to produce 
MMP-1.  Fibroblasts, macrophages and neutrophils can produce MMP-9.91,92,94 Factor 
XII can be degraded by MMP-8, MMP-12, MMP-13, or MMP-14 by proteolysis 
down-stream of the catalytic region at Gly376-Leu377.90,91 Activation of MMPs by 
coagulation serine proteases has recently become a topic of interest for regulating 
vascular remodeling and local inflammatory processes in damaged tissues.  Factor 
XII’s role in vascular regression/matrix degradation was identified through in vitro 
studies with endothelial cell capillary tubes, finding plasma PK induced MMP-1 
activation and contraction of the tubes only in the presence of FXII or HK.92 
Currently there are no reports regarding the interactions of MMPs and FXII in vivo.  
 Vascular remodeling and wound repair normally begin immediately after 
injury.  After damage occurs, hemostasis begins and initiates/coincides with an 
inflammatory response.  Damaged cells release tissue factor, heme proteins, 
superoxide particles and other chemotactic factors that activate platelets and signal 
the immune system, surrounding fibroblasts, endothelial cells, and smooth muscle 
cells to respond.  Platelets adhere to the ECM and release growth factors while 
providing a procoagulant surface for thrombin activation and eventually clot 
formation (as described earlier). Thrombin, plasmin, FXII, complement, and other 
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blood proteins can induce leukocyte chemotaxis and provide growth factors for 
propagating the inflammatory and proliferative responses just beginning.  
Proinflammatory cytokines interleukin-1β (IL-1β), tissue necrosis factor-alpha (TNF-
α), monocyte chemoattractant protein-1 (MCP-1), IL-6 and IL-8 are secreted by 
infiltrating lymphocytes, macrophages and smooth muscle cells to recruit other cells 
and begin matrix degradation via MMP-1,-2 and-9.91-93,95 Degradation of the matrix 
serves to make migration easier, recruit cells (collagen fragments are 
chemoattractants and MMPs can process chemokines) and remodel infrastructure so 
new vessels and cell connections can develop. The inflammatory phase takes place 
from 1 hour to 4 days in large mammals.97 Matrix metalloproteinase-2 
gelatinase/collagenase activity is increased in mice at 4 days post intimal injury98, 
whereas MMP-9 gelatinolytic activity markedly increases at 4 hours.99 Matrix 
metalloproteinase-1 is a collagenase, therefore it would be expected to be increased 
around the same time as MMP-2.  Proliferation involves mesenchymal and epithelial 
cell migration, fibroblast proliferation (to lay down new matrix), and angiogenesis.100 
During the proliferative phase chemokine suppression is increased by IL-10 and 
transforming growth factor β (TGFβ) (it also promotes growth), while angiogenesis is 
promoted by vascular endothelial growth factor (VEGF), fibroblast growth factor-1 
(FGF-1), angiopoeitins, Delta-like ligand 4 (DLL4), plasminogen activators, platelet 
derived growth factor (PDGF), tissue factor, and other factors.101  The proliferative 
phase is considered to take place from four days to two weeks (in mice it is 48 hours 
to 5 days), overlapping with inflammation and the next phase of remodeling.97  
Remodeling involves laying down new collagen matrix thereby suppressing MMP 
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activity with tissue inhibitor of metalloproteinases (TIMPs) and scavenging of debris 
by macrophages.  This final process takes place between 14 days and 2 months in 
large mammals (5 days to 28 days in rodents).97 Not surprising, wound healing 
processes are delayed in hemophiliacs because a multitude of issues must be 
overcome from the lack of proper coagulation pathway(s) interactions.102,103 Precise 
timing of cellular/protein interactions along with proper quantities of factors are 
required in these complex biological processes to avoid a pathological state.  We need 
more in vivo research in areas of hemostasis, fibrinolysis, inflammation, and wound 
repair—especially in the case of FXII. 
 
Experimental Vascular Injury: Methods and Locations 
As anyone may assume, there are many ways to injure a vessel.  The goal of 
this section is to delineate why one general method may be better than the other, and 
why we chose our methods and locations. 
This brief background on vessel differences and thrombi differences is 
mostly derived from the Bodary and Eitzman104 and Whinna105reviews.  Not all 
thrombi are the same in composition and how they develop.  Thrombus formation is 
complex and depends on factors such as blood flow rate, shear stresses, cell types, 
coagulation or fibrinolytic factors present, the amount of collagen/matrix exposure, 
and length of time of stasis to name a few.  The size of the vessel and the thickness of 
its wall matters.  Microvessels (capillaries, arterioles and venules) have smaller 
diameters that can accommodate one or two cell widths, and they have thin (one to 
four layered) walls to contain a slow flow of blood for cellular respiration.  Their thin 
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walls and slow flow allow for easier real-time monitoring of labeled cellular or 
protein interactions at the site of injury.  Circulating tissue factor is more important 
for thrombus formation in microvessels104, 106 whereas vessel wall TF expression is 
more relevant to macrovessel (carotid and inferior vena cava) 107, 108 thrombus 
formation.  Microvessel venules are less sensitive to collagen and thrombin inhibition 
compared to arterioles, however they both respond to inhibition of platelet 
phosphatidylserine (PS).109 Platelet aggregation and the length of time needed to 
interact with the arteriole wall have also been found important in microvessels—this 
may be true in larger arteries but real-time evaluation of this effect is more 
difficult.110 
In fast flowing vessels having high pressure and high stress forces (i.e. thick 
walled arteries) thrombus formation is primarily platelet dependent.  Platelet tethering 
to the vessel wall via the GPIbα receptors (with von Willebrand factor binding)111, 
activation by the GPIIb/IIa receptor112, and thrombin113 are identified factors needed 
during high shear flow conditions and can be induced by the forces114,115.  In mice it 
appears FXII is needed during arterial thrombosis.28 The collagen-rich arterial walls 
provide an activating agent for platelets and FXII after the protective endothelium is 
removed (denuded).  Of course the quantity and quality of platelets are important for 
arterial thrombosis too.  Thrombi formed in the high flow rate arteries are platelet-
rich and have tails that are fibrin rich (where flow is reduced).116  The rapid 
conversion of fibrinogen by platelets and thrombin in these thrombi lead to more 
cross-linking of fibrin strands, thereby incorporating more plasminogen.  These 
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thrombi tend to be more readily lysed by tPA (in their fibrin-rich “red” regions) but 
only during a 3 hour window after formation, for reasons unknown.104,117  
Venous thrombosis development is viewed in the historical context given by 
Virchow in 1855.  Virchow ascribed “a triad” of conditions involving reduced 
hemodynamics of flow (stasis), dysfunction of the endothelium (or injury), and a 
thrombogenic (hypercoaguable) environment are needed for venous thrombus 
development.118,119   Thrombi formed under stasis conditions are thought to be more 
dependent on coagulation factors and fibrinolysis inhibition than rapid platelet and 
thrombin activation.116  The pooling blood may contribute to contact activation and 
endothelial dysfunction, however stasis alone does not appear to induce 
thrombosis.120 Little is known about the exact mechanisms involved.  White blood 
cells (WBC) have been found important in the development88 and resolution of 
venous thrombi.87,89 The availability of cell adhesion molecules (CAMs) and selectins 
(P- and E-selectin) is important for leukocyte transmigration through the vascular 
walls.120  Thrombi formed during low flow conditions tend to have more red blood 
cells and less platelets in their composition121, however platelets are important for the 
formation of a clot regardless of the vessel type.122 
Various mechanical methods of vessel injury can be used experimentally to 
study thrombus formation or resolution.  Arterial studies emulating coronary, carotid, 
or femoral artery damage relevant to human disease conditions generally employ 
chemical materials (ferric chloride, rose Bengal photochemical) or physical trauma 
(forceps, clamps, catheters, brushes, lasers) that are externally or internally applied.105 
The method chosen mostly depends on the animal used, the equipment available, the 
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question being asked, and the molecular/cellular mechanism wanting to be studied.  
We chose a brush injury model because it offered a way to denude endothelial cells 
and cause “mild” intimal injury without generating a large amount of collagen/matrix 
exposure as seen in Folt’s123,124 and ferric chloride methods125.  The mild localized 
damage causes moderate flow alterations (detectable with a Doppler probe) that may 
reflect injury seen in humans patients undergoing endarterectomy and catheterization 
procedures.124  The milder brush damage may reflect or promote a contact activation 
pathway manner of thrombus development. 
 
Objectives Of This Dissertation Research 
 
Many questions concerning FXII and its in vivo roles have developed over 
the years.  The unexpected observations seen in the knock-out mice bring more 
questions about the role of FXII in humans and other species.  The main objective of 
this dissertation work is to define whether FXII deficiency results in altered 
thrombotic and fibrinolytic responses in large, deep vessels after injury.  Additionally, 
we asked if inflammation was reduced in FXII deficients at the site of injury and tried 
to provide insight to the reason (assuming there might be reduced inflammation).  We 
also explored the role of FXII in a skin inflammation model to determine the extent of 
its participation in local inflammation using an endogenously present inflammatory 
agent, the blood cell degradation product heme (or hemin).  Finally, we aimed to 
define the FXII gene defect and protein associated alterations in our cat colony. 
 
  
 
CHAPTER 2  
 
FELINE FXII GENE AND MUTATION 
 
ABSTRACT 
 
Coagulation factor XII (FXII) assists in thrombus formation and may be 
important in cardiovascular and inflammatory mediated diseases. We have identified 
a naturally occurring mutation in the feline FXII gene that encodes a catalytically 
inactive mutant protein. We sequenced the genomic loci encoding factor XII in wild 
type cats and analyzed mRNA sequences encoding FXII in wild type and FXII 
deficient mutants. The feline Factor XII gene comprises fourteen exons ranging in 
size from 57 to 222 base pairs and spanning 11 kilobases on chromosome A1. The 
wild type feline FXII gene encodes a transcript that is 1833 base pair long and 
contains an open reading frame encoding a protein of 610 amino acids. Analysis of 
RNA from factor XII wild type and mutant cats revealed one single base deletion in 
exon 11 of the FXII coding gene in the FXII deficient cats.  The deletion caused a 
frame-shift at L442 (Leu442Cys) resulting in a nonsense mutation, a premature stop 
codon, and a truncated factor XII protein of 561 amino acids. The mutant FXII 
protein lacks the catalytic triad domain located in the C-terminus between His405 and 
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Asp454 explaining its loss of enzymatic activity. This study is the first to identify the 
genomic sequence and structure of the feline FXII gene.  We identified a FXII 
mutation in the domestic cat, providing insights into the origin and nature of feline 
FXII deficiency. 
 
INTRODUCTION 
 
 Deficiency of factor XII (or Hageman factor) was first described in 1955 
in a human patient who lacked plasma enzymatic activity.3 Although FXII deficiency 
does not present as a bleeding tendency, recent evidences indicate FXII may be 
important in maintaining blood clot stability and pregnancy.28,126  The gene encoding 
FXII in multiple species has been sequenced and various mutations have been 
reported in humans. The prevalence of moderate to severe FXII deficiency in humans 
is between 1-5% of a given Caucasian population.5,9  Feline FXII deficiency, first 
reported in 1977 by Green and White127, presents with very similar features to the 
human disease, thus FXII deficient cats represent an invaluable resource for studying 
the role of factor XII in health and disease. As in humans, the prevalence of FXII 
deficiency in domestic cats of the United States is 2%.8 We took advantage of a 
colony of factor XII deficient cats established first by Kier et al.6, to study the 
molecular basis of FXII deficiency.  
 Factor XII is a serine protease that is primarily produced in the liver and 
circulates in the plasma as an inactive precursor enzyme or zymogen. The FXII 
protein is a two-chain molecule consisting of a heavy chain (50,000 Daltons) and a 
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light chain (30,000 Daltons) connected by a disulfide bond.54 The enzymatic activity 
of FXII is contained in a typical serine protease active site located in its light chain 
(C-terminus). A serine protease forms an oxyanion hole after zymogen activation that 
has a nucleophilic serine (Ser) adjacent to a histidine (His), and a buried ‘proton 
accepting’ aspartate (Asp) in the catalytic apparatus.30 The Ser-His-Asp formation is 
referred to as the ‘catalytic triad’.  When the FXII heavy chain contacts negatively 
charged surfaces or misfolded proteins, the FXII zymogen changes conformation to 
expose its serine protease active site in a process termed ‘autoactivation’.31-33  This 
conformational change allows other coagulation factor zymogens, prekallikrein and 
factor XI,  to bind at the newly exposed catalytic triad site and become cleaved to 
kallikrein and factor XIa respectively.  Because autoactivation of FXII is the initial 
step for in vitro coagulation induction, it has been labeled a ‘contact activation factor’ 
and initiator of the intrinsic coagulation pathway.32 Activated FXII (FXIIa) has also 
been shown to bind to cell surfaces via its heavy chain and participate in other 
biological processes such as inflammation and fibrinolysis, however little is known 
about the extent of its participation and its importance in pathological outcomes.32,34  
The heavy chain has amino acid regions that are homologous to fibronectin type I and 
type II, epidermal growth factor, and kringle structural domains. Fibronectin type I 
and II domains can bind extracellular matrix proteins and collagen, and are thought to 
be involved in the cell-mediated binding of FXIIa.54,60  
 In humans, congenital FXII deficiency is caused by a variety of genetic 
defects that result mostly in null defects or loss of function mutants.  The most 
common defect is a single 46C to T nucleotide substitution in the promoter region of 
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exon 1 on one allele (heterozygous) or both alleles (homozygous).9,128  Caucasians 
have a 20% incidence of a 46T (2-6% incidence for a 46T substitution on both 
alleles) resulting in a decreased translation of FXII due to disruption of the translation 
initiation site.  Individuals having this mutation produce less functional protein and 
can have FXII activity and antigen levels at or slightly below standard normal ranges, 
hence they may not be identified with FXII deficiency during coagulation screening 
tests.9,128,129 Very few mutations result in detectable FXII antigen (referred to as 
cross-reacting material positive) however these tend to occur in exons 9 through 14 
and involve amino acid substitutions.9,128-133 Only 3 cases have been reported to carry 
single base deletions and subsequent frame shifts via mutations in either exon 12 
(10590DelC and 10586DelG) or exon 14 (splice site mutation 11397G→A), and all 3 
transcribed mutant proteins are considered unstable.131  
In this manuscript we sequenced the genes encoding the wild type FXII and 
encoding a mutant allele causing FXII deficiency in the cat.  Our findings explain the 
molecular origin of FXII deficiency in cats.   
 
MATERIALS AND METHODS 
 
Animals 
 
 Four normal cats from outside the colony were tested for FXII enzymatic 
activity and considered normal (>85% of a normal cat plasma pool) for FXII levels.  
Three normal (NL) cats were partially sequenced for genomic DNA and RNA, while 
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one cat was fully sequenced.  One severely FXII deficient (homozygote or HZY) 
having <2% activity was completely sequenced for all exons and RNA, and 4 others 
partially sequenced.  Three moderately deficient for FXII (heterozygote or HET), as 
determined by an enzymatic activities between 30-85% of a normal cat plasma pool, 
were partially sequenced for FXII genomic DNA and RNA products. 
  
Factor XII Activity Assays 
 
 A modified one-stage activated partial thromboplastin time (APTT) was 
used to measure FXII coagulant activity (FXII:C) while a chromogenic peptide (S-
2302) was used to measure amidolytic activity.81 A normal platelet-poor citrated 
(3.8%) plasma pool was created using 5 normal cats (outside and colony sources).  A 
homozygote cat plasma pool created from 4 living colony cats identified through 
breeding and APTT test was used as a substrate to dilute plasmas to 1:10, 1:20, and 
1:40 for the FXII coagulant assay.  One hundred micro liters (µl) of prewarmed 
phospholipid reagent (Dade APTT-FSL, Dade Behring Inc., Newark, DE) containing 
kaolin was added to 100 µl of diluted plasma then warmed to 37˚C for 3 minutes 
before 100 µl of prewarmed 25mM CaCl2 was added.  A Stago ST4 coagulation 
analyzer (Diagnostica Stago Inc., Parsippany, NJ) was used to monitor clotting time 
in seconds.  A standard curve was generated using serial dilutions (1:10, 1:20, 1:40) 
of normal cat plasma pool which had been given an assigned value of 100% activity.  
Individual samples (run in duplicate) were compared to this curve and activity 
expressed as percent of a normal cat plasma pool. Chromogenic substrate S-2302 
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(Diapharma Group Inc, OH) H-D-Pro-Phe-Arg-pNA was used to test kallikrein 
activation as an indicator of FXIIa.  Briefly, 25 µl of plasma diluted 1:5 with 0.15M 
Barbital/0.125M NaCl/0.25% bovine serum albumin pH 7.5 is placed in a 96 well 
microtiter plate with 25 µl of APTT reagent (Dade) to achieve a final plasma dilution 
of 1:10.  The plate is incubated at 37˚C for 45 minutes then 50 µl of 0.0005 M S-2302 
in 0.05M Tris/0.05M Imidazole/0.15M NaCl pH 8.2 is added to the activated plasma 
and wells are monitored every 10 minutes at 405nm for 1 hour.  A standard curve of 
serially diluted normal cat pooled plasma is included on the plate to determine a % of 
normal pool activity for each test sample (run in duplicate).  The normal cat FXII:C 
range for our colony is 85-110%. Normal human plasma was run as an internal 
control to assess reagent and machine functions. The addition of the kallikrein 
inhibitors, soy bean trypsin inhibitor (SBTI) and Kallistop (American Diagnostica, 
CT), resulted in no activity seen in normal cat pool plasma therefore it was left out. 
  
Molecular Techniques 
 
 Genomic DNA was extracted from peripheral blood leukocytes or liver 
samples using the Qiagen DNeasy Blood and Tissue kit (Qiagen Inc., Valencia, CA) 
or Promega’s Wizard Genomic DNA Isolation kit (Promega Corp., Madison, WI) 
according to manufacturer’s instructions. The DNA concentration was adjusted to 
100 ng/ml for use in polymerase chain reactions (PCR). The region of the 1.9x cat 
genome (Pontius et al.)134 identified as being a putative ortholog for F12 (cat 
chromosome A1:206664989..206674943) was retrieved using GARFIELD 
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(http://lgd.abcc.ncifcrf.gov/cgi-bin/gbrowse/cat/, Pontius and O'Brien 2007)135. The 
cat sequence was aligned to GenBank sequences representing transcripts for this gene 
from human (NM_000505), mouse (NM_021489), rat (XM_225172, currently 
NM_001014006), cow (XM_883314, currently NM_001075119), and dog 
(XM_546206). Candidate primers were selected in immediately flanking intronic 
sequences located 50 bases upstream/downstream of acceptor/donor splice sites such 
to extend through each identified exon pair (7 exon pairs in total). Primer sequences 
and PCR conditions for each pair are defined in Table 2.1.  A Perkin Elmer GeneAmp 
PCR Systems 9700 thermocycler was used along with Qiagen’s HotStar HiFidelity 
Taq polymerase kit to amplify the specified cDNA. Cycles varied according to primer 
set melting temperature (Tm); 95˚C for 15mins initial denaturing and enzyme 
activation, then generally step down amplifications of 0.3˚C to 1.0˚C decreases per 
amplification step at 10 cycles per temperature were performed (see Table 2.1).  For 
example, primer set genomic DNA Exon 7-8 had: 95˚C for 15min; 94˚C for 45sec, 
60.3˚C for 45sec, 72.0˚C for 1min x10 cycles; 94˚C for 45sec, 60.0˚C for 45sec, 
72.0˚C for 1min x 10 cycles; 94˚C for 45sec, 59.7˚C for 45sec, 72.0˚C for 1min x 10 
cycles; 72.0˚C for 10min, and 4˚C infinity hold. 
Total RNA was extracted from liver tissue samples collected and 
immediately frozen in liquid nitrogen then stored at -70˚C until being processed with 
the Stratagene Absolutely RNA RT-PCR miniprep kit (Stratagene, La Jolla, CA, 
USA) or Invitrogen’s Purelink Total RNA Purification System (Invitrogen Corp./Life 
Technologies Corp., Carlsbad, CA) according to the manufacturer’s instructions.  One 
normal and one HZY cat total RNA were further purified for messenger RNA 
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products using Sigma’s GenElute mRNA Miniprep kit (Sigma-Aldrich, St. Louis, 
MO).  All RNA samples were treated with 1 unit DNase I (Stratagene, La Jolla, CA, 
USA) per microgram RNA for 15-30 minutes at room temperature, then heated to 
65˚C for 10 minutes prior to reverse transcription.  Two-step reverse transcription 
polymerase chain reaction (RT-PCR) of liver RNA was performed in a 20 micro liter 
volume using Promega’s ImProm-II Reverse Transcription System (Promega Corp., 
Madison, WI) under manufacturer’s suggested conditions.  Briefly, each reaction 
included 4µl of 25mM MgCl2, 4µl of 5X buffer, 1µl of reverse transcriptase, 2µl of 
dNTP mix (10mM each), 0.5µl of 2µg/µl random hexamers or 0.8 µg/µl oligo 
d(T)15, 0.3µl of ABI-Perkin Elmer RNase Inhibitor (20U), 4.2 µl of nuclease-free 
water, and 4µl of sample RNA (100-300 ng/µl).  The PCR was then performed using 
GoTaq® DNA Polymerase or Qiagen’s HotStar Hifidelity DNA Polymerase Kit with 
the following conditions: each 25µl reaction contained 5µl cDNA, 5µl GoTaq® 
Reaction or HotStar 5x Buffer, 0.3µl dNTP (10mM) only with GoTaq® DNA 
Polymerase, 0.3µl GoTaq® DNA Polymerase or HotStar Hifidelity DNA 
Polymerase, 0.4µl each primer (50 µM), 0.5µl of 25mM MgCl2 or Qiagen’s 5x Q 
Solution, and 13.1µl nuclease-free water in GoTaq® mix or 13.4µl nuclease-free 
water in HotStar mix. PCR was performed in a Touch-down procedure similar to the 
following: 95˚C for 15 minutes (HotStar polymerase) or 2 minutes (GoTaq® 
polymerase); 94˚C for 30sec, touch-down 62.5˚C for 30 sec then decrease 0.5˚C per 
cycle x 5 cycles, 72˚C for 30 sec; then 30 cycles of 94˚C for 15 sec, 60˚C for 45 sec, 
72˚C for 45 sec, with final holds of 72˚C for 7mins then 4˚C for infinity. (see Table 
2.2 for each primer set’s conditions). PCR products were visualized by 
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electrophoresis on 1.5% Low EEO agarose gel stained with ethidium bromide. Bands 
were excised and cleaned using Qiagen’s QIAEXII kit.  Automated sequencing was 
done by the UNC-CH Automated DNA Sequencing Facility and the University of 
Michigan DNA Sequencing Core.  Analysis was performed using ‘Sequencher 4.8’ 
software (Gene Codes Corp., Ann Arbor, MI). 
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Table 2.1: Primers used for genomic DNA amplification of exons and exon/intron 
boundaries of feline F12 
 
 
Coverage 
of 
Forward primer 5’→ 3’ Reverse primer 5’→ 3’ 
Size 
bp 
PCR conditions 
(annealing temperatures
Exon 
1→2 
ATTCCCAGGACTCAAGGACC ACCTGACCATCTGCACACTCC 637 
56˚C x10 cycles, 
55.8˚C x10 cycles, 
55.5˚C  x 10  cycles 
Exon 
3→4 
CTGTTTTCCAATCAGGCCC GGGTAAGAACTGATGATACCCAG 648 
56˚C x10 cycles, 
55.5˚C x10 cycles, 
55.0˚C  x 10   cycles 
Exon 
5→6 
AAGCAGGTTTGGGTAGGGAC GGTTGCCTAACAGCTTTTCC 548 
59˚C x10 cycles, 
58.5˚C x10 cycles, 
58.0˚C  x 10   cycles 
Exon 
7→8 
AGCTGTTAGGCAACCAGTCG GGCGCTGTTAAAGGGTAAGG 589 
60.3˚C x10 cycles, 
60.0˚C x10 cycles, 
59.7˚C  x 10  cycles 
Exon 
9→10 
CATCTCCCTCTGCCCCAG CCAGACTCTGCGGCACTC 573 
56˚C x10 cycles, 
55.8˚C x10 cycles, 
55.5˚C  x 10   cycles 
Exon 
11→12 
GAAACCCAGCAAGGGACTC CCCTAGTGGTACCAAAGCTGAG 556 
60˚C x10 cycles, 
59.5˚C x10 cycles, 
59.0˚C  x 10   cycles 
Exon 
13→14 
CTGCAACAGAGGCCAGTTAG AGAGGAATCAAACCCAACCC 577 
59.0˚C x10 cycles, 
58.0˚C x10 cycles, 
57.0˚C  x 10   cycles 
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Table 2.2: Primers used for cDNA amplification and sequencing of feline FXII RNA 
Cover
age of Forward primer 5’→ 3’ Reverse primer 5’→ 3’ 
Size 
bp 
PCR conditions 
(annealing temperatures) 
Exons 
1-4 ATGAGGGCTCTCCTGTTCCT  GCTCGAAGTTGGGACTGGTA 241 
62.5˚C*-0.5˚C/cycle x 5 cycles,
60˚C 45sec x 30 cycles 
Exons 
3-5 TTCTCACTGTCACTGGGGAGC  TGAAGTGTTCTGGACAGATGCA  261 
62.5˚C*-0.5˚C/cycle x 5 cycles,
60˚C 45sec x 30 cycles 
Exons 
4-6 GCTACCAGTCCCAACTTCGAGCA AGTGGGCATCAGGACCCTTACAC 288 
62.5˚C*-0.5˚C/cycle x 5 cycles,
60˚C 45sec x 30 cycles 
Exons 
6-8 GAGAAATGCTTTGAGCCTCAGC GCTCTGCAGTCACGTTCCGGTA 364 
61.5˚C*-0.5˚C/cycle x 7 cycles,
58.2˚C 45sec x 30 cycles 
Exons 
7-9 GGATACGCAGGACGCTTCT CTTGCTCTGCAGTCACGTTC 157 
60.5˚C*-0.5˚C/cycle x 7 cycles,
59.0˚C 30sec x 30 cycle 
Exons 
8-9 ACACTGAGGCGCGATGCTACGA TGCAGTGCTGAAAGCGAGGGCA 346 
62.5˚C*-0.5˚C/cycle x 5 cycles,
60.2˚C 45sec x 30 cycles 
Exons 
10-12 GTACTGGCGCCACAATTTCT AGGTCGTGCTGGTAGGTGAT 183 
61.5˚C*-0.5˚C/cycle x 7 cycles,
58.3˚C 45sec x 30 cycles 
Exons 
11-14 TTCTCGCCCATCACCTACC GGTCAGGAATTGGTGTGCTC 500 
60.5˚C*-0.5˚C/cycle x 7 cycles, 
58.3˚C 45sec x 10 cycles, then 
58.5˚C x10 cycles, followed by 
58.7˚C x10 cycles 
Exons 
13-14 ACGTGCACGGAGTCTCTTTT CTGGATGGTCAGGAATTGGT 50 
60.5˚C*-0.5˚C/cycle x 7 cycles,
59.0˚C 30sec x 30 cycles 
*Cat 
GAPDH GCCGTGGAATTTGCCGT GCCATCAATGACCCCTTCAT 82 
Works between 55C-56C for 
30 sec x 30 cycles 
*primer sequences and conditions are from C.M. Leutenegger et al. Vet. Immunology 
and Immunopathology 71 (1999) p. 291-305 
 
Protein Isolation and Identification Techniques 
a) Inhibition of Feline FXII by Corn Trypsin Inhibitor (CTI) and mixing studies 
Mixing studies involving human prekallikrein-deficient (PKd) plasma 
(Sigma Diagnostics) and FXII-deficient plasma (George King Biomedicals, Overland 
Park, KS), corn trypsin inhibitor (Enzyme Research Laboratories, South Bend, IN), 
and specific FXIIa antibodies were performed on normal cat plasmas using the Stago 
ST4 and the modified APTT procedure.  Human PKd plasma was used as a diluent 
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instead of HZY cat plasma pool to rule out a prekallikrein deficiency in our colony.  
Antibodies or corn trypsin inhibitor (CTI) were used to check their ability to inhibit 
feline FXII amidolytic activity.  Plasma duplicates were incubated 15-60 minutes at 
37˚C with each inhibitor prior to performing the APTT.  One normal cat, 3 HZY cats, 
and the HZY cat plasma pool were evaluated in these studies.  An overall 1:2 dilution 
of plasma was used with HZY cat plasmas while a >1:10 dilution of normal cat 
plasma was used because of the extremely short clotting time observed with normal 
cat plasma (<18 seconds at a 1:2 dilution) would not be detected on the ST4.  A 
standard curve was not used, only the ability to correct the prolonged clotting time 
was observed.  Results are given in Table 2.3. 
 
Table 2.3: Mixing and inhibition studies of colony plasmas 
Sample 
Identification 
Sample dilution, diluent or inhibitor 
added  (if any) 
Averaged 
APTT 
(seconds) 
Determination 
NL 0827 cat 1:40 with human PKd plasma 31.5 PK sufficient 
HZY 6034 cat 1:2 with human PKd plasma 46.5 PK sufficient 
HZY 6B1E cat 1:2 with human PKd plasma 46.3 PK sufficient 
HZY 171A cat 1:2 with human PKd plasma 47.7 PK sufficient 
HZY cat pool 1:2 with human FXII-deficient 
plasma 
>200 FXII deficient 
Human PKd 1:2 with barbital-saline buffer* 144.7 PKd;dilutionary 
control 
NL 0827 cat  1:10, 300 ug/ml CTI (10ul volume) 64.7 inhibitory 
NL 0827 cat  1:10, 400 ug/ml CTI (10ul volume) 66.5 inhibitory 
NL 0827 cat  1:10, 500 ug/ml CTI (10ul volume) 92.0 inhibitory 
NL 0827 cat  1:10, 10 ul of saline (vehicle) or 
nonspecific IgG 
<20 control 
NL 0827 cat 1:10, 10 ul of 0.4uM anti-FXII B7C9 20.2 inhibitory 
NL 0827 cat 1:10, 10 ul of 1.0uM anti-FXII B7C9 21.6 inhibitory 
Normal 
Human  
10 ul of 0.4uM anti-FXII B7C9 56 Control; inhibitory 
 
b) Protein electrophoresis and Western blotting (WB) 
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Plasma samples from a normal cat and homozygote FXII-deficient cat were 
subjected to reducing conditions and 12% SDS-PAGE prior to electroblotting onto 
nitrocellulose or polyvinylidene fluoride (PVDF).  The blotted antigens were detected 
with two polyclonal (pAb) anti-human FXII antibodies (purchased from Cedarlane 
[CL20055A] and Affinity Biologicals) and a monoclonal ‘B7C9’ heavy chain specific 
anti-human FXII antibody (a gift from Dr. Robin Pixley) according to conditions 
described by Pixley et al..49 Prestained (Sigma P8748, Bio-Rad Kaleidoscope C3312) 
and unstained (Bio-Rad #80715) molecular weight standards (MW) were used to 
determine the size and migration of detected antigens.  Secondary antibodies of either 
rabbit anti-goat IgG or rabbit anti-mouse IgG conjugated to peroxidase (Sigma 
Aldrich A5420 and A9044) or rabbit anti-mouse alkaline phosphatase (Jackson 
Laboratories) were used and detected with Vector Labs NovaRed or Sigma 
BCIP/NBT B6404 substrates. An example of plasma blotting is given in Figure 2.1.  
Additional studies of feline plasmas involved two-dimensional difference in gel 
electrophoresis (2-D DIGE) with subsequent WB analysis.132  Normal feline plasma 
stained with CyDye3 (green) and HZY feline plasma stained with CyDye 5 (red) 
were run on a pH 3-10 non-linear isoelectric focusing (IEF) followed by 10.5% SDS-
PAGE for the 2nd dimension prior to imaging on ImageQuant software (GE 
Healthcare). Electroblotting and immunodetection were performed as described137, 
using a peroxidase conjugated rabbit anti-goat secondary antibody (Sigma A5420) at 
1:20,000 in Tris buffered saline (TBS)/1% bovine serum albumin/0.1% Tween-20 
and enhanced chemiluminescence (ECL) detection kit (Amersham™ ECL).  The 
membrane was exposed to Kodak Scientific Processing film and developed with a 
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table top film processor. Results of the   2-D DIGE and WB are shown in Figures 2.2 
and 2.3 respectively. 
c) Protein isolation methods 
Normal feline FXII protein was isolated on CTI-CNBr Sepharose 4B and 
pAb (Cedarlane) goat anti-human FXII-CNBr Sepharose affinity columns prepared as 
described by Ratnoff et al.138 and Kier et al.81, respectively.  Briefly, 20-50 milliliters 
of fresh frozen citrated plasma (pH 6.0) was thawed at 37˚C and treated with 100 
ug/ml soybean trypsin inhibitor (SBTI) and 50 ug/ml polybrene (hexadimethrine 
bromide, Sigma Aldrich, St. Louis, MO).  In order to remove contaminating proteins 
including FXIIa, plasmas were run over a benzamidine-HCl bound to agarose column 
and fractions collected.  Those fractions with detectable FXII activity (using the 
APTT assay with HZY cat pool plasma) were dialyzed in appropriate loading buffers 
and further purified over either CTI- or anti-FXII-CNBr Sepharose columns.  Bound 
feline FXII was eluted with 0.05M glycine/50% ethylene glycol buffer pH 3.2 on the 
immunoaffinity column or eluted with a barbital saline buffer (0.15M sodium 
barbital, 0.125M sodium chloride, 100 ug/ml SBTI, 50 ug/ml polybrene) with a linear 
gradient of 0.15-1.5M sodium chloride from the CTI column. Two to 5 ml fractions 
were collected with a LKB optical fractionator, dialyzed/desalted, concentrated and 
tested for FXII antigen (WB) and activity (APTT).  Flow through material was 
collected and re-applied to the column(s) in order to maximize FXII recovery. The 
CTI column was carefully stripped with 0.1M sodium acetate/1.0M sodium chloride 
pH 4.0 then re-equilibrated with barbital saline buffer prior to isolating HZY feline 
plasma FXII as described above. The anti-FXII-CNBr column was stripped with 10 
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ml of 2M guanidine hydrochloride and re-equilibrated with 0.01M Tris/0.5M sodium 
chloride/100ug/ml SBTI/50ug/ml polybrene pH 7.5 buffer prior to use. All fractions 
of HZY plasma with 280 nm absorbance readings above 0.1 were tested for antigen 
and activity.  Results of WB are shown in Figure 2.4 (normal cat) and Figure 2.5 
(HZY cat). 
Figure 2.1: Western Blot of Feline and Human Plasmas With Monoclonal Heavy 
Chain Antibody 
 Normal (lane 3) and homozygote (lane 4) for feline FXII citrated plasma was 
reduced, electrophoresed, then blotted onto PVDF.  Human plasma (lane 5) and 
purified human FXIIa (lane 6) are positive controls. Lane 1 contains purified normal 
cat FXII and lane 2 contains a molecular weight standard (Bio-Rad Kaleidoscope). 
Primary immunodetection was done with a mouse anti-human FXII heavy chain 
(B7C9) monoclonal antibody then detected with a rabbit anti-mouse IgG whole 
molecule alkaline phosphatase conjugated antibody followed by BCIP/NBT 
development.  Arrows indicate expected bands (longer arrow=80 kDa, shorter=50 
kDa) 
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Figure 2.2: 2-D DIGE of One Normal Cat (green) and One Homozygote Cat 
(red) Citrated Plasma  
The circled spots correspond to suspected FXII proteins detected by WB techniques. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                               Enlarged image 
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Figure 2.3: Western Blot of 2-D DIGE 
Primary antibody used for probing was a polyclonal goat anti-human FXII (Affinity 
Biologicals).  Secondary antibody was a peroxidase conjugated rabbit anti-goat IgG 
(Sigma) detected with ECL kit.  The circled spots are suspected feline FXII (upper 
right spot=normal cat, lower left spot=HZY cat). 
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Figure 2.4: Western Blot of Fractions From Normal Feline Plasma FXII Purification 
Lanes are as follows: 1=unstained MW, 2=human FXII deficient plasma, 3=purified 
human FXIIa, 4=normal human plasma, 5=eluted cat fraction 36, 6=cat fraction 35, 
7=cat fraction 34, 8=empty, 9=cat fraction 33, 10=cat fraction 32, 11=flow through 
from FXII immunoaffinity column, 12=benzamidine column eluate.  Primary 
antibody used to probe antigens was mouse anti-human heavy chain (B7C9).  
Secondary antibody was rabbit anti-mouse IgG alkaline phosphatase conjugated that 
was detected with BCIP/NBT. Arrows indicate expected band size (long arrow=80 
kDa, short arrow=50 kDa) 
       1          2         3         4        5       6       7         8        9        10         11        12 
 
 
 
 
Figure 2.5: Western Blot of Purified Mutant Feline Plasma FXII Fractions Using 
     An Anti-FXII CNBr Column 
 Primary antibody was a polyclonal goat anti-human FXIIa (Affinity Biologicals). 
 Lanes are: 1= HZY cat fractions 1&2, 2= HZY cat fractions 1&2 2nd loading of flow 
through material. Arrow indicates an expected band of identity (~66 kDa). 
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RESULTS 
 
 
The feline FXII gene consists of 14 exons and 13 introns which results in a 
protein of 610 amino acids (a.a.) having high sequence similarity to human (80% 
nucleotide, 73% a.a.), and mouse (79% nucleotide, 68% a.a.) FXII genes as shown in 
Figure 2.6.  The coding sequence for one normal cat FXII (accession number 
GQ_981174) and the mutant cat FXII (accession number GQ_981175) were 
determined and submitted to GenBank..  Several polymorphisms were found and 
reported while using the 1.9x cat genomic sequence as an alignment reference for our 
cat samples.  Most of the polymorphisms occurred in exons (7, 8, 10, 11 and 14) yet 
are predicted to yield synonymous substitutions.  The exceptions being a Val→Ala 
change in exon 7, and our colony’s mutation found in exon 11.  
 
Figure 2.6. Nucleotide sequence comparison of mRNA transcripts encoding for 
mature FXII protein  
 
 Shaded areas indicate identical sequence. Dashed lines indicate no nucleotide.  The 
beginning of each exon and the termination codon are indicated by an underlined 
letter with the exon identified above it.  The location of the FXII-deficiency mutation 
in our cats is in exon 11 and indicated by a bold, underlined, boxed red letter. 
 
CLUSTAL 2.0.10 multiple sequence alignment 
       exon 1 
feline       -------------------------------------------------ATGAGGGCTCT 11 
human        CTATTGATCTGGACTCCTGGATAGGCAGCTGGACCAACGGACGGATGCCATGAGGGCTCT 60 
mouse        --------------TCCTGGGCAGGCAGCGGGGCCATCGG-CAGACGCCATGACGGCTCT 45 
                                                               
            exon 2 
feline       CCTGTTCCTGGGGTCCCTGCTGGGAAGCCTGGAGTCAGCGTTTTTGACTCCACCTTGGAA 71 
human        GCTGCTCCTGGGGTTCCTGCTGGTGAGCTTGGAGTCAACACTTTCGATTCCACCTTGGGA 120 
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mouse        GTTGTTCCTGGGGTCTCTGCTGATGAGTCTGGATCTGACACTTTCGGCTCCACCATGGAA 105 
                
 
          exon 3 
feline       AGCCCCTAAGGAGCATGAGCACAGAGCAGATGAGCACACAGTAGTTCTCACTGTCACTGG 131 
human        AGCCCCCAAGGAGCATAAGTACAAAGCTGAAGAGCACACAGTCGTTCTCACTGTCACCGG 180 
mouse        AGACTCCAAGAAATTTAAGGACGCACCTGATGGGCCCACAGTGGTTCTCACTGTGGATGG 165 
 
feline       GGAGCCCTGCTACTTCCCCTTCCAGTACAACCGGCAACTGTACCACACATGCATCCACAA 191 
human        GGAGCCCTGCCACTTCCCCTTCCAGTACCACCGGCAGCTGTACCACAAATGTACCCACAA 240 
mouse        GAGGCTCTGCCATTTTCCCTTTCAGTACCACCGTCAGCTACACCACAAATGCATCCACAA 225 
             
     exon 4 
feline       GGGCCGGCCTGGCCGCCAGCCCTGGTGTGCTACCAGTCCCAACTTCGAGCAGGACCAGCA 251 
human        GGGCCGGCCAGGCCCTCAGCCCTGGTGTGCTACCACCCCCAACTTTGATCAGGACCAGCG 300 
mouse        AAGGCGGCCAGGCTCCCGCCCCTGGTGTGCTACCACCCCCAACTTTGATGAAGATCAGCA 285 
                
        exon 5 
feline       ATGGGCATACTGCCTGGAGCCCAAGAAAGTGAAAGACCACTGCAGCAAACACAGCCCCTG 311 
human        ATGGGGATACTGTTTGGAGCCCAAGAAAGTGAAAGACCACTGCAGCAAACACAGCCCCTG 360 
mouse        ATGGGGATACTGCTTGGAGCCCAAGAAAGTGAAAGACCATTGCAGCAAACACAACCCGTG 345 
 
feline       CCAGAATGGAGGGACCTGTGTGAACATGCCAAAAGGCCCACACTGCATCTGTCCAGAACA 371 
human        CCAGAAAGGAGGGACCTGTGTGAACATGCCAAGCGGCCCCCACTGTCTCTGTCCACAACA 420 
mouse        CCACAAAGGAGGGACATGTATCAACACCCCCAATGGGCCACACTGTCTCTGCCCTGAACA 405 
              
      exon 6 
feline       CTTCACTGGGAAGCACTGCCAGAGAGAGAAATGCTTTGAGCCTCAGCTTTTCCAGTTCTT 431 
human        CCTCACTGGAAACCACTGCCAGAAAGAGAAGTGCTTTGAGCCTCAGCTTCTCCGGTTTTT 480 
mouse        CCTCACTGGGAAACATTGCCAGAAAGAGAAATGCTTTGAGCCTCAGCTTCTCAAGTTCTT 465 
              
 
feline       CCATGAGAAAGAAACATGGCATAGGCTTGAATCGGCGGGTGTGGCCGAGTGCCAGTGTAA 491 
human        CCACAAGAATGAGATATGGTATAGAACTGAGCAAGCAGCTGTGGCCAGATGCCAGTGCAA 540 
mouse        CCACGAGAATGAGCTATGGTTTAGAACGGGGCCAGGAGGTGTGGCCAGGTGCGAGTGCAA 525 
              
            exon 7 
feline       GGGTCCTGATGCCCACTGCAAGCCGCTGGCCAGCCAGGTCTGCCACACCAACCCGTGCCT 551 
human        GGGTCCTGATGCCCACTGCCAGCGGCTGGCCAGCCAGGCCTGCCGCACCAACCCGTGCCT 600 
mouse        AGGTTCTGAGGCTCACTGCAAGCCGGTGGCCAGCCAGGCCTGCAGCATCAATCCGTGCCT 585 
               
 
feline       CAACGGAGGCAGCTGCCTAGAGGCGGAGGGTCACCGCCTGTGCCGTTGCCGGGCGGGATA 611 
human        CCATGGGGGTCGCTGCCTAGAGGTGGAGGGCCACCGCCTGTGCCACTGCCCGGTGGGCTA 660 
mouse        TAATGGGGGCAGCTGCCTCCTCGTGGAGGACCACCCACTGTGCCGTTGCCCTACAGGCTA 645 
              
 
    exon 8 
feline       CGCAGGACGCTTCTGCGACGTAGACACTGAGGCGCGATGCTACGACGGCCACGGGCTTGA 671 
human        CACCGGAGCCTTCTGCGACGTGGACACCAAGGCAAGCTGCTATGATGGCCGCGGGCTCAG 720 
mouse        CACTGGATATTTTTGCGACTTGGACCTTTGGGCGACCTGCTATGAAGGCAGGGGGCTCAG 705 
                 
 
feline       CTACCGCGGCACAGCCGAGACTGTGCTGTCGGGCGCCCGGTGTCAGCCGTGGGCCTCAGA 731 
human        CTACCGCGGCCTGGCCAGGACCACGCTCTCGGGTGCGCCCTGTCAGCCGTGGGCCTCGGA 780 
mouse        CTACCGGGGCCAGGCTGGAACTACGCAATCGGGTGCGCCATGTCAGCGGTGGACCGTGGA 765 
              
 
feline       GGCCACCTACCGGAACGTGACTGCTGAGCAAGCGCTGAACTGGGGACTGGGCGACCATGC 791 
human        GGCCACCTACCGGAACGTGACTGCCGAGCAAGCGCGGAACTGGGGACTGGGCGGCCACGC 840 
mouse        GGCCACCTACCGGAACATGACTGAGAAGCAAGCGCTAAGCTGGGGCCTGGGCCACCACGC 825 
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     exon 9 
feline       CTTCTGCAGGAATCCGGACAACGACACCCGCCCGTGGTGCTTCGTGTGGAGCGGCGACCG 851 
human        CTTCTGCCGGAACCCGGACAACGACATCCGCCCGTGGTGCTTCGTGCTGAACCGCGACCG 900 
mouse        ATTTTGCCGGAACCCAGATAATGACACACGTCCATGGTGCTTCGTCTGGAGTGGCGACAG 885 
               
 
feline       GCTGAGCTGGGAATATTGCCGCCTGGCACGTTGCGAACCCCCAGTCCTAGAGGCTCTTCA 911 
human        GCTGAGCTGGGAGTACTGCGACCTGGCACAGTGCCAGACCCCAACCCAGGCGGCGCCTCC 960 
mouse        GCTGAGCTGGGACTATTGCGGCCTGGAGCAGTGCCAGACGCCAACGTTTGCACCTCT--A 943 
              
 
feline       GTTCC---TGCCTCCAA---CCCAGGTCCCCT------CTGAGCACCCGGATTTTCCCCT 959 
human        GACCCCGGTGTCCCCTAGGCTTCATGTCCCACTCATGCCCGCGCAGCCGGCACCGCCGAA 1020 
mouse        GTT----------------------GTCCC---------TGAGAGTCAGGA------GGA 966 
                     
           exon 10 
feline       GCCCTCGCTTTCAGCACTGCAGAAGCCTCAGCCCCCGACCCCG----CTTTGGGCGCGAC 1015 
human        GCCTCAGCCCACGACCCGGACCCCGCCTCAGTCCCAGACCCCGGGAGCCTTGCCGGCGAA 1080 
mouse        GTCCCCGTCCCAGGCAC------CATCTCTGTCCCATGCACCAAA---------TGACTC 1011 
                
 
feline       GCCGGAGCAGCCCACTCCTCTGCCGAGT---------CCCAGCTGCGGACAACGGCTCCG 1066 
human        GCGGGAGCAGCCGCCTTCCCTGACCAGGAACGGCCCACTGAGCTGCGGGCAGCGGCTCCG 1140 
mouse        GACCGATCATCAGACTTCTCTGTCCAAGACCAACACGATGGGCTGCGGACAGAGGTTCCG 1071 
              
 
feline       GAAACGGCTGTCCTCGCTGAGCCGCGTGGTTGG-GGACTGGTGGTCCCTGCCCGGGGCGC 1125 
human        CAAGAGTCTGTCTTCGATGACCCGCGTCGTTGGCGGGCTGGTGG-CGCTACGCGGGGCGC 1199 
mouse        CAAGGGACTGTCCTCGTTCATGCGCGTGGTGGGCGGACTAGTGG-CTCTGCCTGGGTCGC 1130 
               
 
feline       ACCCCTACATCGCCGCGTTGTACTGGCTCCACAATTTCTGCGCGGGCAACCTCATCGACT 1185 
human        ACCCCTACATCGCCGCGCTGTACTGGGGCCACAGTTTCTGCGCCGGCAGCCTCATCGCCC 1259 
mouse        ACCCCTACATCGCTGCACTGTACTGGGGTAACAACTTCTGCGCGGGCAGTCTCATCGCCC 1190 
              
      exon 11 
feline       CCTGCTGGGTGCTGATCGCGGCGCACTGCCTGCAGAACCGGCCCCCGCCGGAGGAGCTGA 1245 
human        CCTGCTGGGTGCTGACGGCCGCTCACTGCCTGCAGGACCGGCCCGCACCCGAGGATCTGA 1319 
mouse        CCTGTTGGGTGCTGACCGCGGCTCACTGCCTGCAGAATCGGCCAGCGCCCGAGGAACTGA 1250 
             
 
feline       CGGTGGTGCTCGGCCAGGACCGCCATAACCAGAGCTGTGAGCAGGGCCAGACTCTGGGCG 1305 
human        CGGTGGTGCTCGGCCAGGAACGCCGTAACCACAGCTGTGAGCCGTGCCAGACGTTGGCCG 1379 
mouse        CAGTGGTACTTGGTCAAGATCGCCACAACCAGAGCTGCGAGTGGTGCCAGACTCTGGCTG 1310 
             
 
        exon 12 
feline       TGCGCGCCTACCGCCTGCACGAGGCCTTCTCGCCCATCACCTACCAGCACGACTTGGCCC 1365 
human        TGCGCTCCTACCGCTTGCACGAGGCCTTCTCGCCCGTCAGCTACCAGCACGACCTGGCTC 1439 
mouse        TGCGCTCCTACCGCCTTCACGAGGGCTTCTCCTCCATCACCTACCAGCACGACTTGGCTC 1370   
 
 
 
feline       TGCTGCGCCTGCAGGAAAGAGAGGACGGCCACTGCCCGCTGCCGTCGCCTTTCGTTCAGC 1425 
human        TGTTGCGCCTTCAGGAGGATGCGGACGGCAGCTGCGCGCTCCTGTCGCCTTACGTTCAGC 1499 
mouse        TGCTGCGCCTGCAGGAAAGCAAAACCAACAGTTGCGCGATCCTGTCACCTCACGTTCAGC 1430 
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feline       CGGTGTGCCTGCCAAGCAGCGCTGCCCGCCCAGCTGAGGCCGAGGCCGCCCTCTGTGAGG 1485 
human        CGGTGTGCCTGCCAAGCGGCGCCGCGCGACC--CT----CCGAGACCACGCTCTGCCAGG 1553 
mouse        CTGTGTGTCTACCCAGCGGCGCGGCCCCACC--CT----CTGAGACAGTGCTCTGCGAGG 1484 
 
 
        exon 13 
feline       TGGCAGGCTGGGGCCACCAGTTTGAGGGGGCCGGGGAATATTCCAGCTTCCTGCAGGAAG 1545 
human        TGGCCGGCTGGGGCCACCAGTTCGAGGGGGCGGAGGAATATGCCAGCTTCCTGCAGGAGG 1613 
mouse        TGGCCGGCTGGGGTCACCAGTTCGAGGGGGCTGAAGAATACTCCACCTTCCTGCAGGAGG 1544 
 
 
feline       CACAGGTGCCGCTCATCCCTTCTGAGCGCTGCTCCGCCCAGGACGTGCACGGAGTCTCTT 1605 
human        CGCAGGTACCGTTCCTCTCCCTGGAGCGCTGCTCAGCCCCGGACGTGCACGGATCCTCCA 1673 
mouse        CACAGGTTCCCTTTATCGCCCTGGATCGCTGCTCCAACTCTAACGTGCACGGAGACGCCA 1604   
  
                     exon 14 
feline       TTACTTCGGGCATGCTCTGCGCTGGCTTCCTTGAGGGTGGCACCGACGCCTGCCAGGGTG 1665 
human        TCCTCCCCGGCATGCTCTGCGCAGGGTTCCTCGAGGGCGGCACCGATGCGTGCCAGGGTG 1733 
mouse        TTCTCCCTGGGATGCTTTGCGCTGGCTTCTTGGAGGGAGGCACCGATGCCTGCCAGGGTG 1664 
 
 
feline       ACTCCGGGGGCCCGCTAGTGTGTGAGGAGGAGGCCGCAGAGCACCAGCTCGTCCTGCGAG 1725 
human        ATTCCGGAGGCCCGCTGGTGTGTGAGGACCAAGCTGCAGAGCGCCGGCTCACCCTGCAAG 1793 
mouse        ACTCCGGGGGCCCTCTGGTGTGTGAGGAAGGAACTGCAGAACATCAGCTCACCCTGCGCG 1724 
  
 
feline       GCATCGTCAGCTGGGGTTCCGGTTGTGGCGACCGCTACAAACCAGGTGTGTACACCGACG 1785 
human        GCATCATCAGCTGGGGATCGGGCTGTGGTGACCGCAACAAGCCAGGCGTCTACACCGATG 1853 
mouse        GAGTCATCAGCTGGGGCTCCGGCTGTGGTGACCGCAACAAGCCCGGAGTCTACACAGACG 1784 
  
                stop 
feline       TGGCCAGCTACCTGGCCTGGATCCAGGAGCACACCAATTCCTGACCATCCAGAGCGANAT 1845 
human        TGGCCTACTACCTGGCCTGGATCCGGGAGCACACCGTTTCCTGATTGCTCAGGGACTCAT 1913 
mouse        TGGCCAACTACCTGGCTTGGATCCAGAAGCATATTGCTTCATAACTAACCAG-GCTTTAT 1843 
  
feline       TTTTNNNTT--------------------------------------------------- 1854 
human        CTTTCCCTCCTTGGTGATTCCGCAGTGAGAGAGTGGCTGGGGCATGGAAGGCAAGATTGT 1973 
mouse        CCTTCCCTCCTTGTGTGCTCCTTGG----------GATGGGACGATGAATGTGGCATGCT 1893 
                                                     
feline       ------------------------------------------------------------ 
human        GTCCCATTCCCCCAGTGCGGCCAGCTCCGCGCCAG-GATGGCGCAGGAACTCAATAAAGT 2032 
mouse        GGGTCA------CAGTGAAGCTAGTGCCCCGACACTGGGGGCACAGAAACTCAATAAAGT 1947 
                                                                             
feline       ---------------------------- 
human        GCTTTGAAAATGCTGAGAAAAAAAAAAA 2060 
mouse        GCTTTGAAAACGTT-------------- 1961 
 
 
Analysis of the sequenced feline RNAs indicates the FXII gene encodes for 
a mature protein of 610 amino acids and is predicted to contain all the characteristic 
structural domains reported in human FXII, i.e. a Type I and II Fibronectin-like 
domain, two epidermal growth factor (EGF)-like domains, a kringle domain, a 
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proline-rich domain, and the typical trypsin-like serine protease domain of the light 
chain.  The feline light chain’s predicted catalytic triad of His405, Asp454, Ser558 (it is 
His393, Asp442, Ser544 in human FXII) has all 3 amino acids aligning with the human 
translated sequence.  However, only 2 of the 3 kallikrein cleavage sites in human 
(Arg334-N335 and Arg343-Leu344) FXII share homology with the cat sequence as 
illustrated in Figure 2.7.  Using the  
 
 
Figure 2.7: Amino Acid Sequence Homology of Normal Cat, Human, and Mutant Cat 
FXII   
 
Regional alignment of predicted normal and mutant feline FXII protein sequences 
compared with human. Teal highlighted amino acids indicate potential kallikrein 
cleavage sites, yellow highlighted a.a. are members of the well conserved serine 
active site or catalytic triad (Ser-His-Asp) which is linked to the heavy chain by a 
disulfide bond (indicated by highlighted green).   The light grey colored a.a. sequence 
is a portion cleaved off at the signal peptidase site after secretion of the protein.  The 
red colored a.a. indicate the nonsense sequence caused by the mutation in the colony. 
 
Normal cat     MRALLFLGSLLGSLESAFLTPPWKAPKEHEHRADEHTVVLTVTGEPCYFPFQYNRQLYHT 60 
human          MRALLLLGFLLVSLESTLSIPPWEAPKEHKYKAEEHTVVLTVTGEPCHFPFQYHRQLYHK 60 
mutant cat     MRALLFLGSLLGSLESAFLTPPWKAPKEHEHRADEHTVVLTVTGEPCYFPFQYNRQLYHT 60 
               *****:** ** ****::  ***:*****:::*:*************:*****:*****:  
 
normal cat     CIHKGRPGRQPWCATSPNFEQDQQWAYCLEPKKVKDHCSKHSPCQNGGTCVNMPKGPHCI 120 
human          CTHKGRPGPQPWCATTPNFDQDQRWGYCLEPKKVKDHCSKHSPCQKGGTCVNMPSGPHCL 120 
mutant cat     CIHKGRPGRQPWCATSPNFEQDQQWAYCLEPKKVKDHCSKHSPCQNGGTCVNMPKGPHCI 120 
               *:******:******:***:**:**********************:********.****: 
 
normal cat     CPEHFTGKHCQREKCFEPQLFQFFHEKETWHRLESAGVAECQCKGPDAHCKPLASQVCHT 180 
human          CPQHLTGNHCQKEKCFEPQLLRFFHKNEIWYRTEQAAVARCQCKGPDAHCQRLASQACRT 180 
mutant cat     CPEHFTGKHCQREKCFEPQLFQFFHEKETWHRLESAGVAECQCKGPDAHCKPLASQVCHT 180 
               **:*:**:***:********::***::* *:* *.*.**.**********: ****.*:* 
 
normal cat     NPCLNGGSCLEAEGHRLCRCRAGYAGRFCDVDTEARCYDGHGLDYRGTAETVLSGARCQP 240 
human          NPCLHGGRCLEVEGHRLCHCPVGYTGPFCDVDTKASCYDGRGLSYRGLARTTLSGAPCQP 240 
mutant cat     NPCLNGGSCLEAEGHRLCRCRAGYAGRFCDVDTEARCYDGHGLDYRGTAETALSGARCQP 240 
               ****:** ***.******:*::**:*:******:* ****:**.*** *.*.**** *** 
 
normal cat     WASEATYRNVTAEQALNWGLGDHAFCRNPDNDTRPWCFVWSGDRLSWEYCRLARCEPPVL 300 
human          WASEATYRNVTAEQARNWGLGGHAFCRNPDNDIRPWCFVLNRDRLSWEYCDLAQCQTPTQ 300 
mutant cat     WASEATYRNVTAEQALNWGLGDHAFCRSPDNDTRPWCFVWSGDRLSWEYCRLARCEPPVL 300 
               *************** *****.*****.**** ****** . ******** **:*:.*.  
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normal cat     EA  LQFLPPTQVP  SEHPDFPLPSLSALQKPQPPTP ALGATPEQPTPLP   SPSCG 352 
human          AAPPTPVSPRLHVPLMPAQPAPPKPQPTTRTPPQSQTPGALPAKREQPPSLTRNGPLSCG 360 
mutant cat     EA  LQFLPPTQVP  SEHPDFPLPSFSALQKPQPPTP ALGATPEQPTPLP   SPSCG 352 
                
normal cat     QRLRKRLSSLSRVVGGLVALPGAHPYIAALYWLHNFCAGNLIASCWVAEPRAHCLQNRPP 412 
human          QRLRKSLSSMTRVVGGLVALRGAHPYIAALYWGHSFCAGSLIAPCWVLT AAHCLQDRPA 419 
mutant cat     QRLRKRLSSLSRVVGGLVVPARGAPLHRRVYWRHNFCAGNLIASCWVAEPRAHCLQNRPP 412 
               ***** ***::*******.   . *    :** *.****.***.***    *****:**. 
 
normal cat     PEELTVVLGQDRHNQSCEQCQTLGVRAYRLHEAFSPITYQHDLALLRLQEREDGHCALPS 472 
human          PEDLTVVLGQERRNHSCEPCQTLAVRSYRLHEAFSPVSYQHDLALLRLQEDADGSCALLS 479 
mutant cat     PEELTVVLGQDRHNQSCEQCQTLAVRAYRCTRPSRPSPTSTTWPCCACRKERTATARSRR 472 
               **:*******:*:*:*** ****.**:**       
 
normal cat     PFVQPVCLPSSAARPAEAEAALCEVAGWGHQFEGAGEYSSFLQEAQVPLIPSERCSAQDV 532 
human          PYVQPVCLPSGAARP  SETTLCQVAGWGHQFEGAEEYASFLQEAQVPFLSLERCSAPDV 537 
mutant cat     LSFSRCACQAALPAQLRPRPPSVRWQAGATSLRGPGNIPASCRKHRCRSSLLSAAPPRTC 532 
                 
    Ser active site 
normal cat     HGVSFTSGMLCAGFLEGGTDACQGDSGGPLVCEEEAAEHQLVLRGIVSWGSGCGDRYKPG 592 
human          HGSSILPGMLCAGFLEGGTDACQGDSGGPLVCEDQAAERRLTLQGIISWGSGCGDRNKPG 597 
mutant cat     TESLLLRACSALPSLRVAPTPARVTPGARstop                            561 
                   
 
normal cat     VYTDVASYLAWIQEHTNS----------------------------------------   610 
human          VYTDVAYYLAWIREHTVSLLRDSSFPPWFRSERVAGAWKARLCPIPPVRPAPRQDGEE   615 
mutant cat                           561 
                      
 
prediction program SignalP3.0, a signal peptidase cleavage site has been suggested 
between a. a. position 16 and 17 (LysGluSer-AlaPhe) in the feline FXII protein, 
indicating the secreted protein would be 594 a. a. in length.139   A mutation consisting 
of a deletion of one ‘c’ nucleotide in exon 11 was found in all FXII-deficient cats 
tested (see Figure 2.6 and Figure 2.6 Supplemental for identified base).  As expected, 
the homozygote cats had the deletion on both alleles whereas the heterozygotes had 
only one allele affected.  We discovered a single nucleotide polymorphism of a c>t 
nucleotide change at this site in one normal cat that helped to determine which ‘c’ had 
been deleted.  The deletion mutation appears to result in a reading frame-shift during 
translation which would yield a nonsense amino acid sequence with a premature stop 
codon.  Exons 11 through 14 encode most of the trypsin-like serine protease domain 
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(active site). This nonsense mutation is predicted to be expressed as a truncated, 
catalytically inactive protein that retains normal fibronectin Type I and Type II, EGF-
like, and kringle domains as shown in Figure 2.8.  
 
Figure 2.8: ExPASy ScanProsite Domain View of Predicted Normal vs. Mutant feline 
FXII Protein 
 
The normal feline FXII shares complete domain homology with human FXII by 
having a Fibronectin Type II, a Fibronectin Type I, a kringle, a trypsin, and two EGF-
like, domains.  The mutant feline protein is predicted to lack the trypsin domain, thus 
having no serine protease catalytic activity. 
 
        
Normal Feline FXII 
  
  
 
 
Mutant Feline FXII 
 
 
 
 
 
 
Analysis of the predicted feline FXII proteins revealed many interesting 
characteristics.  The theoretical isoelectric point (pI) and molecular weight (MW) for 
normal feline FXII are 6.02 and 67.4 kDa, respectively.  The predicted/theoretical pI 
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and MW for the mutant protein are 9.01 and 62.5 kDa, respectively.140   Predictions 
of arginine cleavage sites (autoactivation or kallikrein cleavage sites in human FXII) 
suggest that normal and mutant feline FXII  have one site at amino acid Arg364-Val365 
(site a.a. sequence RLSSLSR|VV) similar to human,  however the human FXII has an 
additional site at Arg345-Glu346 (R345-E346) based on the ProP v.1.0b ProPeptide 
Cleavage Site Prediction program (see Figure 2.6 for locations).141  Mouse FXII also 
has one predicted site at Arg354 in the same region of the C-terminus, suggesting 
activation differences may exist between human and other mammals.   
Protein studies of plasma and purified feline FXII confirm some of the 
predicted characteristics.  According to WB analyses with various antibodies directed 
to human FXII, the feline reduced protein migrates at about 67 kDa as seen in Figures 
2.1, 2.4 and 2.5.  Table 2.3 illustrates that normal feline plasma has expected 
prekallikrein cleavage ability and can be inhibited with CTI and a monoclonal heavy 
chain anti-human FXII antibody (directed against Thr134 through Arg153).  Human 
studies show similar enzymatic inhibition properties using both agents.39,142  When 
the purified and concentrated fractions of FXII protein from normal cats were added 
to a homozygote cat plasma pool, the activated partial thromboplastin time (APTT) 
was corrected to near normal values (from >200 seconds corrected to 33.6-43.1 
seconds) indicating the purified FXII protein was intact and active and that there was 
not a potential inhibitor of the FXII activity in the mutant plasma.  When the 
abnormal FXII protein was isolated from deficient cat plasma, no correction of the 
APTT was given, further indicating the primary defect in FXII is present in the 
mutants. Mutant feline FXII was detected in plasma samples and purified fractions 
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using various antibodies (see Figures 2.1, 2.3, 2.5).  The apparent size of the mutant 
FXII protein is close to 66 kDa (as seen in Figure 2.5) with its heavy chain of 
appropriate size (50 kDa) recognizing the monoclonal antibody B7C9 (Figure 2.1).  
Using isoelectric focusing and reduced SDS-PAGE separation (Figure 3b, circled, red 
dot) followed by western blot analysis (Figure 3c, circled), the mutant FXII protein 
has a slightly different migration pattern than the wild-type protein. These results 
demonstrate that feline FXII is enzymatically similar to the human protein, that the 
mutant feline factor lacks activity, and that its truncation is due to the single 
nucleotide cytosine deletion. Under isoelectric focusing and reduced SDS-PAGE (2-
D DIGE) conditions it appears the mutant FXII protein expressed in the plasma has a 
slightly different migration pattern (Figure 2.2 circled, red dot).  Western blot 
analysis with a polyclonal anti-human FXII antibody suggests the two identified spots 
(circled) in Figure 2.3 should be FXII proteins which correspond with the identified 
gel proteins (Figure 2.2 circled). 
 
DISCUSSION 
 
 This study has confirmed sections of the LGD 1.9x WGS cat genome and 
successfully identified normal and abnormal feline mRNA transcripts coding for 
FXII.  The mutation identified in exon 11 of our FXII-deficient cat colony is the first 
molecular characterization of this defect in domestic short haired cats.  Although no 
identical nonsense mutation has been described in humans, other single base deletions 
in exons 12 and 14 result in similar phenotypes.131 Studies of our HZY cat plasmas 
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indicate a catalytically inactive cross reacting material-positive protein, as detected by 
various commercially available polyclonal and monoclonal anti-human FXII 
antibodies, may be expressed. The active site and heavy chain binding site appear to 
be similar in feline and human FXII according to their amino acid sequences and 
protein studies.  In humans, the heavy chain has high homology with urokinase and 
tissue plasminogen activator, along with type II fibronectin regions which may 
contribute to FXII’s binding to cellular surfaces and collagen, respectively.49,54,60   
Corn trypsin inhibitor is thought to bind in the carboxy-terminal region of the light 
chain in an area distinct from the active site142, possibly explaining why the mutant 
cat FXII protein is able to bind the CTI-CNBr affinity column yet not have enzymatic 
activity.  Our studies suggest the expressed mutant cat FXII protein retains a portion 
of its C-terminal light chain region yet lacks the proper active site--in agreement with 
the predicted protein characteristics.  However we cannot eliminate the possibility 
that our antibodies are detecting some other cross-reacting protein able to activate 
FXII (thus inhibited by antibody and CTI) when tested in an APTT assay as shown in 
Table 2.3. Studies in plasmas from certain FXII-deficient humans indicate that amino 
acid alterations occurring in the C-terminal region of the protein can yield an 
expressed protein lacking enzymatic function.  The human variant FXII Washington 
has a G to A nucleotide change in the 3’splice acceptor site of exon 14 that causes the 
exon 13-exon 14 splicing product to lack one nucleotide. This splice site mutation 
results in a Cys571 to Ser replacement that translates to a detectable truncated 
transcript with a disrupted active site.143  Other cross reacting material-positive 
mutations in  FXII deficient patients were identified as an Arg353 to Pro (FXII 
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Locarno) substitution in exon 10 resulting in a loss of the kallikrein cleavage site144, 
and a substitution (Trp486 to Cys) in exon 12 resulting in a reduced translation and a 
reduced secretion of FXII due to incorrect protein folding.132  Most likely the severity 
of the predicted changes to our colony’s mutant FXII protein would result in a 
misfolded protein that is subject to rapid proteasome degradation.145 Further studies 
of the mutant cat FXII protein are needed in order to determine the expression status 
and sequence of their predicted protein.   
 In conclusion, new insights into the molecular characterization of feline 
FXII have been gained.  Identification of the FXII genetic defect causing a loss of 
coagulant and amidolytic activity in a research colony of cats will aid in future 
analyses of studies investigating the in vivo role of FXII. 
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Figure 2.6 Supplemental: Chromatogram of Feline Nucleotide Sequence Analysis 
Showing Mutation Detection 
Arrow indicates the SNP c>t nucleotide change that identified which ‘c’ is deleted. 
 
 
 
 
 
 
 
  
 
 
CHAPTER 3 
 
VASCULAR INJURY RESPONSES IN  
A FELINE MODEL OF FXII DEFICIENCY 
 
 
ABSTRACT 
 
 Vascular injury of the endothelium and exposure of the intima can lead to 
thrombosis and subsequent activation of the fibrinolytic and immune systems in vivo.  
Factor XII (Hageman factor) can contribute to all of them simultaneously. Humans 
with FXII deficiency have no bleeding problems after surgery or intravascular 
procedures.4 Mice deficient in FXII, however, do not form stable occlusive thrombi 
after arterial injury which appears to be related to collagen-induced FXII activation 
and platelet interactions.35 We used a feline model of congenital FXII deficiency to 
evaluate thrombotic, fibrinolytic, and inflammatory changes after venous and arterial 
injuries.  Cats deficient in FXII formed stable occlusive thrombi in femoral veins and 
arteries at the same rate as normal animals.  However, contralateral vein injuries 48 
hours later showed significantly delayed thrombus formation in FXII deficient cats.  
Fibrinolysis, thrombin generation, and fibrinogen plasma levels were reduced but not 
significantly in deficient animals. Fibrinogen degradation products were present in 
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only one deficient and 2 normal cats. Leukocyte numbers in veins, MMP-1 and 
MMP-9 expression in veins were significantly lower in FXII deficient cats in 48 hour 
old vein segments. Leukocyte and/or platelet interactions with FXII in the developing 
thrombus may play a significant role in vivo.  Factor XII may have a greater impact 
on inflammatory responses and the ability to resolve a formed thrombus more so than 
hemostasis. 
 
INTRODUCTION 
 For many years the importance of the role of FXII in vivo has been 
disputed.  Humans and animals lacking FXII activity do not have bleeding problems 
and seem to form pathological thrombi, thus it was thought to be unimportant in 
coagulation.  Researchers and clinicians argue over whether FXII deficiency is related 
to thrombophilia because studies in humans have yielded controversial results, 
possibly due to unknown risk factors individuals may carry and the inability to 
control other factors.  In recent years targeted gene deletion mouse models have been 
created to study in vivo properties of FXII.  The mice studies have yielded many new 
unexpected findings of its role in thrombosis, however new questions arose as to 
whether these findings are species specific and possibly not reflective of thrombus 
formation in humans. 
 The current thinking of the hemostatic and thrombotic processes may 
change based on new discoveries about FXII.   When a vessel is injured, collagen and 
matrix underneath the protective endothelial cells is exposed.  The pericytes and 
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adventitial cells surrounding the endothelial cells express tissue factor that combines 
with blood factor VIIa and activates other coagulation proteases involved with 
clotting.36-38 Tissue factor initiated clotting is termed extrinsic (not from the blood) 
and is thought to be the first pathway of coagulation triggered after traumatic vessel 
injury.  Factor XII was first identified through in vitro studies as an initiator of 
coagulation (intrinsic pathway) when blood deficient in FXII did not clot in a glass 
test tube.3 Activation of FXII was found to require a negatively charged surface, such 
as glass or metals, however a normally present physiological i.e. in vivo substance 
was not identified until recently. Exposure of Type I collagen fibers34 as seen in 
traumatic vascular damage and misfolded proteins35 present in certain inflammatory 
disease states can activate FXII in vivo. The activation of the intrinsic coagulation 
pathway provides a way to amplify thrombin generation during thrombosis.  
Thrombin is critical in thrombosis because it cleaves fibrinogen into fibrin strands 
which then provide a network to trap cells and proteins needed for a stable thrombus 
formation.  Thrombin also activates other coagulation factors, in particular FXI, 
which can activate FXII thereby accelerating the clotting process.  In the absence of 
FXII, a thrombus can still form because of the TF/VIIa pathway. The FXII deficient 
mice experiments open new questions as to whether the unstable clots could embolize 
and become pathologic thrombi somewhere else.35 Those who argue no firm evidence 
of a thrombophilia risk exists for severely FXII deficient humans point to many 
familial and large population studies showing no associations.13,14,26  The FXII 
controversy raises serious concerns about species differences and mechanisms of 
hemostasis, thrombosis and fibrinolysis.  The feline model of FXII deficiency may 
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help answer this question. The congenital FXII deficiency in cats was first described 
by Green and White.127 We took advantage of a colony of factor XII deficient cats 
established first by Kier et al.6, to study thrombosis, fibrinolysis, and inflammatory 
differences associated with FXII deficiency. 
 
MATERIALS AND METHODS 
 
Animals 
 Animal care was provided in accordance with the procedures outlined in 
the "Guide for Care and Use of Laboratory Animals" (National Research Council; 
1996; National Academy Press; Washington, D.C.) and in accordance with a protocol 
approved by the Institutional Animal Care and Use Committee of the University of 
North Carolina at Chapel Hill.  Domestic breeder cats (Felis catus) were received 
from P. Bresnahan and limited in-breeding performed to maintain the line.  Animals 
were phenotyped for FXII activity (FXII:C) based on a modified APTT clotting assay 
as described by Kier et al.81and in Chapter 2.  Factor XII:C levels of <2% of a normal 
cat plasma pool defined cats as homozygote (HZY), <85% but >2% of a normal cat 
plasma pool as heterozygote (HET), and >85% as normal (NL).  No spontaneous 
bleeding tendencies or thrombotic events have been observed in the colony.  No 
cardiomyopathies, immunodeficiencies or autoimmune problems have been observed.   
 One female and 8 male HZY cats were compared to 4 female and 3 male 
NL cats (6 derived from outside sources).  The ages of the animals varied from 1 year 
to 11 years, all are considered adult animals. 
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Surgical procedures 
  
 Animals were fasted 8 hours prior to surgery.  All cats were anesthetized 
before venepuncture and surgical procedures with a mixture of ketamine (20mg/ml/kg 
body weight) and acepromazine maleate (0.11mg/kg body weight).  Atropine sulphate 
(0.25 mg) was given at the time of intubation.  Isoflurane gas inhalation (1-3% with 
oxygen) was used to maintain anesthesia through out the procedure.  Sterile surgical 
technique was used. Each animal received 250 ml of saline over the course of the 
surgery.  No heparins or anticoagulants were used.  Blood pressure, pulse, heart rate, 
body temperature were monitored with Vetspecs VSM6 (Canton, GA) and 
respirations were charted from the time of intubation until the animal was extubated. 
All exposed vessels were moistened with sterile saline-soaked gauze to prevent 
drying. Animals were revived, placed on antibiotics and analgesics, and monitored 
until they could return to the colony.  Two separate surgeries were performed on each 
animal as follows. 
 Day 1: The right femoral artery and femoral vein were isolated and 
baseline blood flow monitored with 20-MHz Doppler flow probe (Indus Instruments). 
Data from the Doppler probe were collected on an Apple iMac using a PowerLab 
4/20 and Chart software (ADInstruments, Colorado Springs, CO).  Blood flow was 
primarily monitored on the femoral vein after injury since the artery required ligation 
upon catheter removal. A one millimeter disposable cytology brush purchased from 
Wilson-Cook Medical (Winston-Salem, NC) was introduced into a branching 
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saphenous vein (distal to the site of injury) and fed cranially to the main portion of the 
common/external femoral artery or vein approximately 10 cm caudal to the aortic 
bifurcation. Figure 3.1 illustrates the spatial relationships of the injury site.  The brush 
was chosen based on the apparent diameter of the vessel with the intention to have a 
close but not too tight fit in order to introduce a moderate amount of intimal damage.  
Arterial saphenous branches were too narrow in general for our smallest brush, 
therefore we introduced the catheter-sheathed brush directly into the common femoral 
artery.  This required ligation of the artery at the catheter introduction site afterward. 
Visual monitoring was used for thrombosis formation proximal to the ligature.  The 
brush was released from its sheath five times before removing the catheter from the 
animal. Pressure was applied at the introduction site until bleeding was stopped.  The 
probe was placed on the site of injury and flow rates monitored until flow stopped 
(permanent cessation of flow or PCF) or until 240 minutes was reached.  Blood 
samples were taken immediately distal to the injury site (considered ‘local’ samples) 
at timed intervals (0, 5, 15, 30, 60, 90, 120, 180, and 240 minutes) after injury or up 
to the moment of PCF. Additional ‘systemic’ blood samples were taken from the 
cephalic or jugular veins at timed intervals of presurgery, 30, 90, 180, and 240 
minutes. After the venous injury was made and initial blood samples collected, the 
femoral artery injury procedure began (usually around 70 minutes after venous 
injury).  The Doppler probe was removed for the 15 minute procedure.  Arterial 
injury was made similar to the venous injury, however only a pre-injury blood sample 
was taken, i.e. no further blood samples were taken.  No Doppler flow measurements 
were taken on the artery.  Blood flow and visual changes were noted at the site of the 
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injury. Surgery was ended by closing the wound site with absorbal (polyglycolic acid) 
and non-absorbal (ethilon) exterior suture material. Antibiotics (ampicillin and 
amoxicillin) were administered for 10 days. 
Day 3: The above anesthesia and prepatory procedures were made on the 
same cat at 48 hours after the first surgery.  The left femoral vein and artery were 
isolated and injured as described above.  The same blood sampling procedures were 
followed.  At the end of blood flow monitoring or 240 minutes, all injured vessels 
were retrieved.  Vessels were placed in 10% neutral buffered formalin for 48 hours 
then 70% ethyl alcohol prior to standard histological processing (at the UNC 
Lineberger Cancer Center Histopathology Lab).  Tissue orientation was done by silk 
suture attached to the end of the vessel located cranial to the injury site (referred to as 
the proximal end). Animals were then euthanized or revived for later terminal studies. 
Figure 3.1: Injury Site Diagram For Femoral Vessels 
 The catheter-sheathed brush (grey line) was introduced in the branch of the 
saphenous vein (thin arrow) then fed caudally to ~10 cm before the aorta.  
Five repeated brushings (red area, thick arrow) were made in the femoral vein 
or artery.    
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Blood Sampling 
 
Blood was collected into plastic syringes either having 3.8% sodium citrate 
pH 6.0 preloaded to achieve a 1:9 ratio of sodium citrate to blood respectively, or 
directly placed into BD Vacutainer tubes with ethylenediaminetetraacetic acid 
(EDTA). Samples were immediately placed on ice (except EDTA samples).  Citrated 
blood was spun at 10,000 relative centrifugal force (rcf) for 6 minutes at 4˚C, then the 
platelet poor plasma was immediately separated and stored at -70˚C until used.  
Samples for blood indices (complete blood count or CBC) were mixed well at room 
temperature and analyzed on a Beckman Coulter ACTdiff (Miami, FL) automated 
blood analyzer that was set for feline blood cell parameters.  Frozen plasma samples 
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were thawed at 37˚C then stored on ice when assayed.  All samples were run in 
duplicate for all assays except for fibrinogen degradation products in which 2 
different concentrations of plasma were tested. A normal cat plasma pool was made 
from cats that had not been used for experimental procedures.  
 
Hemostasis Assays 
 
 Thrombin Assay: The thrombin specific chromogenic substrate 
BIOPHEN CS-01 (38) was purchased from Aniara (Mason, OH) and used at a 
concentration of 1.25 mg/ml. Plasma samples were first removed of their fibrinogen 
by incubating equal volumes of plasma with 10% polyethylene glycol (PEG)-8000 
for 6 minutes at room temperature.146 They were centrifuged at 10,000 rcf for 3 
minutes and the supernatant removed for further assay steps.147  One hundred 
microliters (µl) of  defibrinated plasma was diluted with 27 µl of 0.05M Tris-
HCl/0.3M sodium chloride buffer pH 8.4 and 10 µl of activated partial 
thromboplastin time (APTT) reagent (Dade) then incubated at 37˚C for 4 minutes in a 
96 well microtiter plate (Costar EIA/RIA plate). Eight microliters of chromogenic 
substrate containing 100 µg/µl of soy bean trypsin inhibitor (SBTI) was added to each 
well using a multichannel pipetor. One reading was for absorbance at 405nm was 
immediatelyl taken with a Bio-TEK EL600 (Bio-TEK Instruments, Winooski, VT., 
U.S.A.) spectrophotometeric plate reader. Ten microliters of 180 mM calcium 
chloride was added.  Readings at 405nm were taken every 30 seconds for 30 minutes. 
A normal cat plasma pool was used to generate a standard curve using serial dilutions 
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(undiluted, 1:2, 1:4, 1:8) of defibrinated plasma. The undiluted sample was assigned a 
value of 100% activity with serial dilutions representing 50%, 25%, and 12.5% 
respectively. Normal human plasma was run on every plate as an internal control to 
assess reagent and machine functions.  Percentage of thrombin generated was 
determined by plotting the optical density values against time and calculating the time 
to one half of the maximum velocity reached (½Vmax) for each time point, then 
extrapolating their value from a curve generated from the normal cat pool’s time to ½ 
Vmax.  Samples that were clotted upon thawing were not used.  
 
Factor XIIa: As desribed in Chapter 2, chromogenic substrate S-2302 
(Diapharma Group Inc, OH) H-D-Pro-Phe-Arg-pNA was used to test kallikrein 
activation as an indicator of FXIIa.  Briefly, 25 µl of plasma diluted 1:5 with 0.15M 
Barbital/0.125M NaCl/0.25% bovine serum albumin pH 7.5 is placed in a 96 well 
microtiter plate with 25 µl of APTT reagent (Dade) to achieve a final plasma dilution 
of 1:10.  The plate is incubated at 37˚C for 45 minutes then 50 µl of 0.0005 M S-2302 
in 0.05M Tris/0.05M Imidazole/0.15M NaCl pH 8.2 is added to the activated plasma 
and wells are monitored every 10 minutes at 405nm for 1 hour.  A standard curve of 
serially diluted normal cat pooled plasma is included on the plate to determine a % of 
normal pool activity for each test sample (run in duplicate).  The addition of the 
kallikrein inhibitors, SBTI and Kallistop (American Diagnostica, CT), resulted in no 
activity seen in normal cat pool plasma therefore it was left out. 
 Fibrinogen (% of normal pool): A turbidimetric fibrinogen method148 
was modified for use with small sample volumes.  The lower detection limits of this 
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method are reported as 0.2 grams/L.  Standard curves of normal cat pool plasma and 
purified clottable bovine fibrinogen (Sigma-Aldrich) were generated on every plate 
by running serial dilutions (undiluted, 1:2, 1:4, 1:8) and assigning a value of 200% to 
the undiluted pooled plasma sample.  All samples were run in duplicate. The method 
is as follows: Citrated test plasmas (25 µl) were diluted 1:2 with 6% bovine serum 
albumin (BSA)/ 10 mM Na2HPO4/138 mM NaCl/2.7 mM KCl /400 µg/ml polybrene 
pH 7.4 in a 96 well microtiter plate.  One reading was taken at 405 nm room 
temperature to determine a time zero (pre-clotting) absorbance value.  One hundred 
microliters of 6% BSA/ 10 mM Na2HPO4/138 mM NaCl/2.7 mM KCl /400 µg/ml 
polybrene/0.3IU/ml bovine thrombin pH 7.4 were added to each well, being careful to 
avoid bubbles. Bovine thrombin was aliquoted and stored at -20˚C to preserve its 
quality and avoid interassay variations.  Absorbance increase (∆A) was measured 
every 30 seconds for 20 minutes at 405nm.  Change in absorbance versus time was 
plotted for the standard curve and the area of the curve showing the greatest linearity 
was chosen for comparing ∆A/minute. Usually this time of greatest linearity was 
between 3 minutes and 5 minutes.  The test sample values were extrapolated from the 
standard curve and reported as percentage of normal cat pool plasma. Four 
homozygotes and one normal experimental cat were not assayed due to compromised 
samples. 
 Fibrin Degradation Products (FDP): A commercially available latex 
agglutination kit assay for FDP was purchased from Diagnostica Stago catalog # 
00540 and used according to manufacturer’s instructions.  Briefly, test plasmas were 
diluted 1:2 and 1:8 with Reagent 2 (a glycine buffer). Twenty microliters of diluted 
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plasma are mixed with 20 µl of Reagent 1 (latex beads coated with a mouse 
monoclonal anti-human FDP antibody).  The reagents are mixed on a special card and 
rocked for exactly 3 minutes.  A determination of “positive” or “negative” is made by 
comparing agglutination patterns to manufacturer supplied controls.  The detection 
limit for this assay is 2.5 µg/ml.  A positive result in a 1:2 diluted sample reflects a 
level of >5 µg/ml FDPs. This kit is used at the North Carolina School of Veteriniary 
Medicine (Raleigh, NC) clinical diagnostic lab for feline patients and proven to work 
in our cat plasmas by tPA treating a clot and testing it after 4 hours.  Only presurgery 
and 240 minute citrated plasma samples were tested for FDPs. 
Fibrinolytic Ability Assay:  This is a modified65 fibrin plate lysis assay in 
which a plasma dextran sulfate euglobulin fraction (DEF) is mixed with a fibrinogen-
plasminogen reagent in a microtiter plate.  Thrombin and calcium are added and a 
fibrin clot forms.  Plasminogen activating factors present in the DEF will lyse the clot 
and the optical density (∆ % Transmittance at 405nm) is monitored over time.  The 
details of this procedure are as follows.   
DEF preparation (on ice): One hundred microliters of citrated plasma was 
mixed with 800 µl of cold sterile distilled water then 100 µl of cold sterile dextran 
sulphate (100 mg/L) then 0.25% acetic acid in this order. Samples were vortexed 
briefly then spun at 12,000 rcf at 4˚C for 10 minutes.  Supernatants were removed by 
pipetting and 100 µl of sterile 0.05 M Sodium Barbital/ 0.1M NaCL/0.25% 
gelatin/2.7mM EDTA pH 7.75 was added to the pellet for resuspending the 
precipitate.  Next 1.6 µl of flufenamic acid (final concentration of 4mM) in 0.25M 
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sodium hydroxide was added to the precipitate and mixed well until all elements 
appeared dissolved.  For samples receiving plasminogen activator inhibitors, 0.5 µl of 
mouse anti-human uPA (200µg/ml from NeoMarkers Ab-2) and 1 ul of goat anti-
human tPA (50µg/ml from American Diagnostica #387) were added to 23.5 µl of the 
DEF and incubated 30 minutes at 37˚C. A normal cat pool plasma DEF (100%) and a 
“no DEF” (buffers only) were used as controls that received 1.5 µl of non-immune 
mouse sera instead of specific antibodies. 
For Fibrin Clot Formation:  Purified, clottable (>95%) bovine fibrinogen 
(Sigma-Aldrich) was prepared fresh daily using the same buffer (sterile and 
refrigerated).  An equal volume of  0.2% (weight/volume) fibrinogen in 50mM 
Sodium Barbital/HCl pH 7.75 was mixed with an equal volume of a 1 Clottable Unit 
(CU)/ml human Lys-plasminogen (Hematologic Technologies Inc, Essex Junction, 
VT) in 150mM sodium chloride to achieve a final concentration of 0.1% 
fibrinogen/0.5 CU/ml plasminogen.  One hundred microliters of 0.1% plasminogen-
rich fibrinogen (final concentration) was added to a polypropylene 300 µl capacity 96 
well microtiter plate well.  Samples were run in duplicate. Twenty-five microliters of 
DEF were added to the fibrinogen mixture and gently mixed.  Twenty-five microliters 
of 36 Unit (NIH)/ml of bovine thrombin diluted in 20mM CaCl/0.1% Tween-80 were 
added and immediately mixed by gentle tapping of the plate.  The microtiter plate 
was monitored at room temperature on the Bio-TEK EL600 (Bio-TEK Instruments, 
Winooski, VT, U.S.A.) spectrophotometeric plate reader at 405nm for 24 hours with 
readings 1 hour apart.  A standard curve of normal cat plasma pool DEF (undiluted, 
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1:2, 1:4, 1:8 dilutions with 150mM sodium chloride) was generated for calculations in 
which undiluted DEF was given a value of 100%.  The percent transmittance will 
increase over time as the clot is lysed by plasminogen activators in the DEF. The time 
to reach ½ Vmax was determined for each test sample and compared against the 
standard curve to calculate the percentage of normal cat plasma fibrinolytic ability. 
Antibodies for uPA and tPA were tested for their cross reactivity to cat  tPA by 
immunodetection on a Western Blot assay as described in Chapter 2 and by 
fibrinolytic plate assay described above.  Normal cat plasma was diluted and run 
under reducing conditions in a 12% SDS-PAGE.  The gel was transferred to a 
membrane, blocked with 5% milk, then the primary goat anti-human tPA was 
incubated overnight at 4˚C at a 1:200 dilution in Tris Buffered Saline (TBS)/1% 
Bovine Serum Albumin (BSA). A rabbit anti-goat IgG peroxidase conjugated 
antibody (Cappel Worthington) used at 1:2000 in TBS/1% BSA for 2 hours. Human 
plasma was run as a control and molecular weight determinations of antigens detected 
were done by comparison to a molecular weight marker (Sigma P8748).  Results are 
shown in Figure 3.2. Anti-uPA was not detectable with Western Blotting however its 
ability to inhibit plasminogen activity in the fibrin plate assay was evaluated in 
normal cat pool plasma.  Serial increases of antibody placed in normal cat plasma 
DEF caused a reduction of clot lysis as expected for inhibition.  Normal human 
plasma DEF was run as a control.  Results of the uPA inhibition study are shown in 
Figure 3.3. The amount of lysis reflects the overall fibrinolytic ability (plasminogen 
activators and their inhibitors) of the test subject.  Reduced lysis reflects either few 
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plasminogen activators are present, or an increased level of plasminogen activator 
inhibitors is present. 
 
 
Figure 3.2: Western Blot of Goat Anti-Human tPA On Cat Plasmas 
Lane1=kaleidoscope MW marker, Lane 2=empty, Lane 3=Normal human plasma 
1:20, Lane 4=Normal cat plasma 1:20, Lane 5=HZY cat plasma 1:20.  Thick arrow 
indicates expected band for two-chain tPA at 70 kDa, thin arrow indicates expected 
band for sc-tPA at 40 kDa (very faint bands for cat plasmas). 
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Figure 3.3:  uPA Antibody: Inhibition Studies on Cat Fibrinolytic Activity 
Normal Cat Pool Plasma With Anti-uPA
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Histopathology Evaluation and Staining 
 
 Standard Hematoxylin and Eosin Evaluation: Tissue samples were cut 
in half cross-sectionally, oriented with the cut edges (middle of the injured area) 
down for sectioning, were dehydrated in alcohols, embedded in paraffin, and serially 
cut at 5 micrometers (µm).  Two pieces or three pieces of vessel were included on 
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each slide. The first section of the tissue block was stained with Mayer’s Hematoxylin 
and eosin (H&E) by the UNC LCCC Histopathology Lab, with the remaining serial 
unstained sections for immunohistochemical staining (IHCS).  A single trained 
evaluator (D.E.B) performed damage score assessments and leukocyte counts 
(cell#/hpf) of H&E stained slides by the following methods. 
 
 Damage Score Assessment: An arbitrary system was created to rank the 
damage of the vessel wall and the presence of attached and/or occlusive thrombi.  The 
assumption was made that damage into the deeper layers would provide more 
thrombogenic material thus a thrombus would be present and attached.  Scores range 
from minimal damage (1) to severe damage (5).  Since 2-3 separate regions of the 
injured area were evaluated, scores were averaged for each animal then means were 
compared using a Mann-Whitney U test.  A p value <0.05 was considered significant. 
The rating system is as follows: 
 
1=endothelium disrupted minimally; thrombus may or may not be present.  
          
2=endothelial and intimal damage of 50% or more of the surface area; thrombus may 
or may not be present.         
   
3=25% of the media is damaged along with endothelium and most of the intima is 
removed; attached luminal thrombus may be present. .    
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4= ~50% of the media remains (no other layers present), much hemorrhage to the 
media, luminal thrombus is attached and >80% occluding if present.   
        
5=almost no media present, the adventitia has much hemorrhaging, a luminal 
thrombus is attached and >80% occluded.  
 
 Inflammatory Cell Number Evaluation:  Each vessel was assessed for 
an average number of leukocytes present per high power field (20x).  A grid system 
was used to maintain consistency and prevent biasing by the evaluator.  A vessel was 
divided into 5 regions as compared to a clock face: 12-O’clock, 3-O’clock, 6-
O’clock, 9-O’clock and the center point. Each region was counted at 20x for all 
leukocytes present for a total of five hpf counts.  The five regions were then averaged 
and the means were compared using the Mann-Whitney U test in order to measure 
inter-group differences having large variances.  A p value of <0.05 was considered 
significant. 
Immunohistochemistry Methods: All tissue sections were deparaffinized 
and rehydrated in xylenes (5 minutes x 2), 100% ethanol (3 minutes x 2), 95% 
ethanol (3 minutes x 2), 75% ethanol (3 minutes x 2), 50% ethanol (3 minutes x 2), 
then phosphate buffered saline (PBS) for 3 minutes x2 washings.  Endogenous 
peroxidases were blocked with 0.3% (v/v) aqueous hydrogen peroxide in methanol 
for 19 minutes.  Tissues were then subjected to heat-induced antigen retrieval using a 
microwave method149 and citrate buffer.  Briefly, slides were submerged in 0.1M 
citrate buffer pH 6.0 and heated to 100˚C and maintained for 18 minutes by 
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intermittent starting and stopping of the microwave.  Slides were allowed to gradually 
cool to room temperature before washing with PBS.  Tissues were block of non-
specific proteins at room temperature for 30-60 minutes with the appropriate normal 
sera or milk (5%) according to the secondary antibody species used.  The primary 
antibody was applied at a defined dilution for overnight incubation at 4˚C. Table 3.1 
shows the specific details of each antibody used.  The MMP-1 and MMP-9 were 
previously reported to work in cat tissue.150 
 
Table 3.1:  Antibodies Used For Immunohistochemistry of Vessels 
1' antibody clonality species blocking agent 1' dilution 2' antibody 2' dilution
MMP-1 Lab Visions Corp, Ab-6 poly rabbit goat 1:50 goat-HRP 1;200
MMP-9 Lab Visions Corp, purified, 9234-p1 epitope specific rabbit goat 1;100 goat-HRP 1;200
tPA Innovative Research, purified on protein G poly sheep horse 1:50 donkey-HRP 1;100
uPA Innovative Research, antiserum poly rabbit anti-mouse goat 1:50 goat-HRP 1;300
 
 
The secondary antibodies, horse radish peroxidase (HRP) labeled goat anti-rabbit or 
donkey anti-sheep (Sigma-Aldrich), were diluted in PBS/1% BSA, and applied at 
room temperature for 1 hour.  Slides were washed three times in PBS/0.1% Tween-20 
then developed with Vector Labs NovaRed and counterstained with 0.01% (w/v) 
Methylene blue stain.  Tissues were washed in water then dehydrated in the same 
series of alcohols and xylenes before permanently coverslipping.  A positive control 
tissue slide of cat placental tissue was run with each batch of staining.  Positive 
staining is indicated by a red precipitate against a light blue background.  The primary 
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antibody was not added for negative control specimens (no 1˚).  Each tissue stained 
had a negative control along side of it (the next serial section). 
 
Staining Evaluation:  The intensities of immunohistochemical staining for 
uPA, tPA, MMP-1, and MMP-9 were ranked in a semi-quantitative blinded manner 
by 1 histologist (DEB), using a scale from 0 to 3 as follows: 
(0) indicating no staining (background);  
(1) indicating weak staining in a few cells and/ or matrix;  
(2) indicating weak staining in the majority of cells or strong staining in a few cells 
and/or matrix;  
(3) indicating strong positive staining in the majority of cells and/or matrix. 
 
 The observations were made in the media-intima area of cross-sections (1-3 
tissue pieces per cat) of the injured region of the vessel.  Two uninjured vessels 
collected from an area about 10 centimeters distal to the injury site were stained for 
MMPs only.  Differentiation was made between the cellular staining intensities versus 
matrix component staining intensities.  The mean score for staining intensity of cells 
in each animal was compared within groups and between groups using an analysis of 
variance (ANOVA) and Mann-Whitney U test with a p value <0.05 indicating 
significance.  The mean score for staining intensity of matrix components in each 
animal was compared within groups and between groups using an analysis of 
variance (ANOVA) and using a Mann-Whitney U test with a p value <0.05 indicating 
significance.  A total staining intensity was made by averaging the cell staining mean 
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value with the matrix staining mean value of each animal, then comparing the total 
staining intensity means of each group using a Mann-Whitney U test.  
 
Statistical Analysis: 
 
The statistical software Statmost 32 (Dataxiom) was used for analyses. The 
arithmetic means were used for most analyses except the time to 50% flow reduction 
which had large positive outliers therefore the median and nonparametric 
comparisons were used.  For statistical purposes, a cat that did not have a 50% flow 
reduction during the experiment was given the value “240”.  One standard deviation 
(SD) value was used as a measure of variance around the mean. Comparisons of 
between group means were made using a one-way ANOVA and Mann-Whitney U 
test.  When the sample distribution was found to be normally distributed, an unpaired 
Student’s t-test was employed to compare means.  Linear correlations of damage with 
50% flow reduction, cell numbers in veins, and IHCS staining intensities were done 
using the Spearman’s rank correlation.  Groups are identified as severely deficient in 
FXII (HZY), normal FXII levels (NL), first day of surgery (Day 1), second surgery 
48 hours later (Day 3), vessel retrieved after 4 hours (4 hr), and vessel retrieved after 
48 hours (48 hr). 
 
RESULTS 
A. Venous Blood Flow Changes 
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There was no difference between groups in the time taken to achieve a 50 
percent reduction in blood flow velocity upon first injury of the right femoral vein 
(Day 1).  However, after injury on the contralateral (left) leg femoral vein (Day 3), 
the HZY were significantly impaired in forming thrombi compared to NL cats of Day 
3.  There were no significant differences between Day 1 and Day 3 values. The 
results are given in Figure 3.4. 
Figure 3.4: Time Taken To Achieve A 50% Reduction In Blood Flow 
Homozygote cats (circles) had a median time to occlusion of 12.2 minutes on 
first vein injury (Day 1), while normal cats (triangles) median time was 10.1 minutes.  
Upon contralateral leg injury (Day 3), homozygote cats median time (51.8 minutes) 
was significantly longer (asterisk indicates p=0.03 at 95% confidence interval) than 
normals (4.5 minutes) using a Mann-Whitney U test for Day 3 only. 
 
 
*
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   Analysis of the number of cats having a permanent cessation of blood flow 
(PCF) after the brush injury is given in Table 3.2.  A PCF is indicated on Doppler by 
a flow velocity measurement of less than 15 Hz/ms with no spontaneous return to 
flow.  The percentage of animals having a PCF on Day 1 was nearly the same for 
both groups (67% HZY vs. 57% NL).  However, a dramatic difference is seen on Day 
3.  None of the HZY cats formed occlusive thrombi in their femoral vein, whereas 
43% of the normals did. 
 
B. Hematological Parameters: 
 
Complete blood cell counts were measured pre-surgery for each cat and 
values are listed in Table 3.2.  Platelet counts were evaluated on the blood smears 
made for each cat and indicated normal numbers present.  Machine platelet counts 
were unreliable due to platelet clumping and size differences.  A significant elevation 
of WBCs was seen at Day 3 for both groups, however between groups (HZY vs. NL) 
WBC counts were not significantly different as shown in Figure 3.5 There was a 
significant decrease (p=0.04) in HCT between Day 1 and Day 3 for HZY, but again 
no intra-group differences.  No excess bleeding was observed to explain this 
difference in hematocrit. 
 
Table 3.2: Individual Animal Data: Blood Flow Reductions, WBC, and HCT Values 
FXII:C (FXII clotting activity), if PCF (permanent cessation of flow) occurred 
is a yes (Y) or did not occur is a no (N) and the percentage of animals that had PCF, 
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WBC (white blood cell count) values are multiplied by 103 to indicate the number of 
cells per cm2, and HCT (hematocrit) values are listed as percentage of packed red 
blood cells.  Averages listed are means +/- SD except for 50% flow reductions are 
given in medians.  
 
Phenotyping 50% flow reduction 50% flow reduction WBC HCT% WBC HCT%
sex age FXII:C Day 1 (mins) Day 3 (mins) Day 1 PCF Day 3 PCF Day 1  Day 1  Day 3  Day 3
HZY 1 M 10 Y <1% 12.2 8.5 Y N nd nd nd nd
HZY 2 M 4 Y <2% 3.2 56.8 Y N 10.1 27.4 17 21.8
HZY 3 M 4 Y <2% 16.6 13.1 Y N 9.8 35.1 16.8 24.6
HZY 4 M 4 Y <2% 4.3 >240 Y N 8 31 nd nd
HZY 5 M 3 Y <2% 89.9 123.3 N N 17.4 29.5 19.7 27.5
HZY 6 M 3 Y <2% 2.1 7.2 Y N 7.3 25.6 11.1 24
HZY 7 M 3 Y <2% 110 8 N N 5.6 29.6 13.7 28.9
HZY 8 M 3 Y <2% 53.1 51.8 N N 10.3 26 nd nd
HZY 9 F 8 Y <1% 2.5 >240 Y N 6.9 25.5 17.1 23.8
median= 12.2 median= 51.8 67% 0% 9.4+/-3.6 28.7+/-3.3 15.9+/-3.0 25.1+/-2.6
NL 1 M 2 Y 99% 6.5 3.1 Y N 12.7 27.6 26.1 34
NL 2 M 1 Y 101% >240 10 N Y 9.37 27.6 21.4 23.8
NL 3 M 1 Y 96% 11 1.1 N N 8.9 28.1 12.9 25.2
NL 4 F 2 Y 105% 3.8 240 Y N 9.5 29.6 20.8 25.6
NL 5 F 1 Y 93% 4.4 4.5 Y Y 8.6 31.5 10.4 21.1
NL 6 F 11 Y 86% 10.1 4.5 Y Y 9.9 21.6 26.1 19.9
NL 7 F 1 Y 100% 20 2.5 N N 5.72 26.5 11.1 19.7
median= 10.1 median= 4.8 57% 43% 9.2+/-2.1 27.5+/-3.1 18.4+/-6.8 24.2+/-5.0
 
Figure 3.5: Differences in Systemic WBC Counts 
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C. Hemostasis Parameters 
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Thrombin Levels:  Although HZY cats had lower levels of thrombin 
generation compared to NL animals, only one time point showed a significant 
difference yet another was nearly significant.  The 30 minute cephalic “systemic” was 
significantly different with a p=0.025 and the 120 minute (p=0.052) was nearly 
significant on Day 3.  Not all animals and time points were tested therefore statistical 
analysis were only done on presurgery, 0, 30, 30 cephalic, 90, 180, and 240 minutes 
after injury samples. Numbers of animals analyzed were: HZY (n=3 to 5) and NL 
(n=4-6).  Figure 3.6 compares means of both groups at each sampling time point (in 
minutes). 
 
Figure 3.6: Thrombin Levels Before And After Injury For Each Day 
The “t0 artery” refers to a sample taken from the femoral artery prior to 
injuring.  This time point varied but generally it was collected between 60 and 90 
minutes. Pre (ceph) refers to presurgery sample taken from the cephalic vein.  The 
“30 ceph” refers to a 30 minute sample taken from the cephalic vein. 
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FXIIa levels:  Only the NL cats were analyzed for FXIIa.  No significant 
differences were seen between days or across time points.  A general decrease in 
FXIIa level was seen on both days from the initial presurgery time point (see Figure 
3.7) 
Figure 3.7: Factor XIIa Levels In Normal Cats Before And After Injury 
The line graph depicts the change in activated FXII through the duration of 
the surgeries on Day 1 and Day 3.  Homozygote cats have no FXIIa therefore they 
were not assayed. Data is shown as means +/- SD.  
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Fibrinogen levels: No significant differences were seen in any parameters.  
Standard deviations were large and numbers of HZY samples were low (n=3). A 
general increase in fibrinogen was seen on Day 3 in all animals, possibly reflecting an 
acute phase physiological inflammatory response by the animals. Data means are 
shown in Figure 3.8. 
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Figure 3.8:  Fibrinogen Levels Before and After Injury 
 
Fibrinogen Levels
0.0
20.0
40.0
60.0
80.0
100.0
120.0
140.0
160.0
180.0
200.0
pre 0 5 30 60 90 120 180 240
Time (minutes)
Pe
rc
en
t o
f N
o
rm
a
l C
at
 
Pl
as
m
a 
Po
o
l (m
ea
n
s)
HZY Day 1
NL Day 1
HZY Day 3
NL Day 3
 
 
 
 
FDPs:  Only three animals in total (HZY #5, NL #5, and NL #6) had a 
positive agglutination at 1:2 dilution in their 240 minute sample on Day 1, indicating 
a level of FDPs being >5 ug/ml.  No other positive FDPs were seen. 
Fibrinolytic Ability: There were significant differences seen in early time 
points (presurgery, 0, 5, 30 minutes) between the HZY and NL groups.  Comparisons 
of means were performed on DEF samples and not the anti-uPA and anti-tPA treated 
clots.   Large variations of individual samples of each group made the anti-uPA and 
anti-tPA plasminogen activator blocking data unreliable so only the no antibody 
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treated wells were used for comparisons.  Figure 3.9 shows a plot of fibrinolytic 
activity (plasminogen activating activity) over the time course of the surgery(s).  
Normal cats started with 36% more fibrinolytic activity than HZY (p value is 0.067) 
on Day 1.  The group means +/- SD are as follows:  
 
 NL Day 1 presurgery:  82.5 % +/- 18.6  
 HZY Day 1 presurgery: 54.4 % +/- 30.4 
    
NL Day 3 presurgery:  55.5% +/- 32.6 
HZY Day 3 presurgery: 55.9 % +/- 20.4 
 
 
   After 5 minutes, a significant reduction of fibrinolytic activity (p=0.028) 
developed on Day 1 in the HZY compared to the NL plasma as illustrated in Figure 
3.9. The 30 minute time points from Day 1 also showed significantly reduced levels 
of FXIIa (p=0.018) as well as the 30 minute cephalic source (systemic) p=0.05 
between groups (Mann-Whitney U) as shown in Figure 3.7. No other time points 
were significant for fibrinolytic activity.  Additional comparisons of data revealed no 
significant correlations with FXIIa or thrombin levels.  We normally see a 25-40% 
reduction in fibrinolytic ability between non-experimental normal and homozygote 
cat plasma DEFs when run in this assay. 
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Figure 3.9: Fibrinolysis Activity of Plasma DEF Before and After Injury 
The change in fibrinolytic ability is shown below for both normal and 
homozygote groups.  Data is depicted in means.  The standard deviation (SD) is 
shown only for the normal cats on Day 1 since the variances are large in all groups. 
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D. Histological Findings 
 
Damage Scores:  Table 3.3 contains the means and a one standard deviation 
variance for the amount of damage assessed due to brush injury.  A nomenclature of 
“4 hours” and “48 hours” is given to vessels from the groups of Day 3 and Day 1 of 
injury respectively. This time refers to the length of time the injured vessels remained 
in the body.  No significant differences were found between damage scores.  The 
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higher amount of damage seen in arteries is probably related to the small size of the 
artery compared to the brush diameter.  Unfortunately no smaller size brushes were 
available to try. 
 
Table 3.3: Damage Score and Leukocyte Counts of H&E Stained Vessels 
Data is given in means +/- SD. One asterisk (*) indicates significance between 
4 hour vein groups i.e. HZY vs. NL.  Two asterisk (**) indicates significance 
between HZY 4 hour vein vs. NL 48 hour vein.  
 
Damage Score
4hr vein 48hr vein 4hr artery 48hr artery
mean+/-SD mean+/-SD mean+/-SD mean+/-SD
HZY 1.7+/-0.8 2.9+/-1.2 3.1+/-1.9 3.0+/-1.6
n= 7 7 7 7
NL 2.6+/-1.6 2.6+/-2.6 3.1+/-1.1 3.6+/-0.9
n= 7 7 7 7
Vessel Leukocyte Counts
4hr vein 48hr vein 4hr artery 48hr artery
 WBC #/hpf  WBC #/hpf  WBC #/hpf  WBC #/hpf
mean+/-SD mean+/-SD mean+/-SD mean+/-SD
HZY 84+/- 42 113+/-60 99+/-95 155+/-109
n= 9 7 9 7
NL 153 +/- 74 164+/-52 112+/-73 155+/-93
n= 7 7 7 7
* **
 
 
 
Leukocyte Counts of Injured Vessels:  The average number of white blood 
cells counted per 20x high power field (hpf) of vessel is given in Table 3.3.  A 
significant difference in WBC/hpf was found between HZY 4hour veins and NL 4 
hour veins (p=0.039 Mann-Whitney U) and between HZY 4 hour veins and NL 48 
hour veins (p=0.009 Mann-Whitney U).  No differences were found in arteries.  The 
 90 
amount of damage only correlated with leukocyte numbers for the HZY 48 hour vein 
samples, having a correlation value of 0.8046 and a p value of 0.029.  It is uncertain 
why there is a correlation only in this group. 
 
Immunohistochemical Staining Results:   
MMP-1 Staining: The staining pattern was separately scored for cells and 
matrix components (vessel wall and advential regions) since MMPs are present in 
both and may function differently. Upon analysis of each parameter (cells staining 
positive versus matrix components staining positive) in HZY versus NL, significant 
differences were seen.  Normal cats had higher intensities in cells (p=0.0165 
ANOVA) and in matrix components (p=0.0086 ANOVA) staining positive.  There 
was significantly more staining in the vein matrix than in artery matrix for NL cats in 
their 48 hour vessels (p=0.012 Mann-Whitney U).  The HZY cats did not show this 
vein>artery matrix intensity difference. At 48 hours the HZY cats had more cellular 
staining in their vein segments compared to their vein matrix staining (p=0.021). The 
staining pattern (cell>matrix) was nearly significant (p=0.052) in 4 hour vein 
segments. Arterial segments had much larger significant differences in cell versus 
matrix staining positive within groups (i.e. HZY 4 hour versus 48 hour) for both HZY 
and NL cats (p<0.001).  Comparisons between groups (NL vs. HZY) showed a 
significant increase in total staining of the NL veins (derived by averaging cell 
intensity and matrix intensity values in each grouping) at 48 hours using the Mann-
Whiney U test.  Table 3.4 outlines these differences.  Seven normal and 9 
homozygote cats were evaluated for MMP-1 staining intensity. 
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 Table 3.4: Intensities of Staining Scores for MMP-1 and MMP-9 
 
MMP-1 
HZY NL
mean+/- SD mean +/- SD
4hr Vein cells 1.9 +/- 0.4 2.4 +/- 0.5
4hr Vein matrix 1.1 +/- 1.1 1.3 +/- 0.7
48hr Vein cells 2.0 +/- 0.8 *2.6 +/- 0.4
48h Vein matrix 1.0 +/- 0.5 **2.2 +/- 0.8
4hr Artery cells 2.8 +/- 0.4 2.6 +/- 0.9
4hr Artery matrix 0.9 +/- 0.5 0.7 +/- 0.7
48hr Artery cells 2.7 +/- 0.4 2.6 +/- 0.5
48hr Artery matrix 0.9 +/- 0.6 0.8 +/- 0.7
 MMP-9
HZY NL
mean+/- SD mean +/- SD
4hr Vein cells 1.9 +/- 0.4 2.4 +/- 0.5
4hr Vein matrix 1.1 +/- 1.1 1.3 +/- 0.7
48hr Vein cells 2.0 +/- 0.8 *2.6 +/- 0.4
48h Vein matrix 1.0 +/- 0.5 **2.2 +/- 0.8
4hr Artery cells 2.8 +/- 0.4 2.6 +/- 0.9
4hr Artery matrix 0.9 +/- 0.5 0.7 +/- 0.7
48hr Artery cells 2.7 +/- 0.4 2.6 +/- 0.5
48hr Artery matrix 0.9 +/- 0.6 0.8 +/- 0.7
*p=0.049 vs HZY 48hr
**p=0.009 vs. HZY 48hr
+p=0.023
+p=0.012
 
 
 
 
 MMP-9 Staining: The same approach as in MMP-1 was used with MMP-
9.  Nearly identical results were seen (see Table 3.4).  Normal cats had higher 
n = 9 n = 7 
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intensities in cells (p=0.0081 ANOVA) and in matrix components (p=0.0004 
ANOVA) compared to the HZY. The only other difference was the p value for the 48 
hour NL vein matrix versus 48 hour NL artery matrix was slightly higher (p=0.023 
using a Student’s t-Test since the distributions were normal).  Seven normal and 9 
homozygote cats were evaluated for MMP-9 staining intensity. 
In summary of the MMP staining data, NL cats had significantly more 
MMP-1 and MMP-9 expressed in their veins at 48 hours than the HZY cats.  Normal 
cats also had more MMP expression in their vein matrix compared to their arterial 
matrix.  The HZY cats did not have this vein>artery matrix staining difference.  When 
all parameters (cells and matrix) were averaged together, the NL cats showed a 
significant increase in total MMP-1 staining of their arteries compared to their veins 
at 48 hours (p=0.005 Student’s t-Test).  This increased artery MMP-1 staining 
correlated positively with the number of WBCs in their (NL) arteries (p=0.039, 
correlation coefficient of 0.8332) at 48 hours.  In contrast, combining all parameters 
for MMP-9 staining in the NL cats at 48 hours showed an increased staining intensity 
in their veins compared to their arteries.  No other significant correlations were seen 
with MMP staining and WBC per high power field.  No significant correlations were 
seen between the damage score and MMP staining, or between MMP-1 and MMP-9 
in all combinations tested. 
Urokinase plasminogen activator and tPA staining:  Only 3 animals in each 
group were stained with these antibodies.  No specific positive control was available 
so the pattern of staining fibrin strands and endothelial cells was the indicator for 
specificity and quality of staining.  There were no differences found in uPA or tPA 
 93 
staining intensities between animal groups or vessel types. The limited number of 
animals stained did not allow for correlation analysis. Microphotograph examples of 
all stainings are given in Figure 4.0. 
 
The staining intensities for each group are as follows (mean +/-SD): 
 
uPA:    HZY 48hr Vein  2.7 +/- 0.6 
  NL 48hr Vein   2.7 +/- 0.3 
 HZY 4hr Artery  2.25 +/- 0.4 
 NL    4hr Artery  2.25 +/- 0.4 
 
tPA:    HZY 48hr Vein  1.7 +/- 0.6 
 NL 48hr Vein  1.6 +/- 1.2 
 HZY 48hr Artery 2.1 +/- 0.9 
 NL    48hr Artery 2.2 +/- 0.7 
 
Figure 4.0: Examples of Immunohistochemitry Staining 
 All photos are at 10x magnification unless otherwise stated. Positive 
staining is indicated by a purplish-red precipitate.  Bright blue coloring is the background 
stain. 
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IMMUNOHISTOCHEMISTRY STAININGS FOR CATS 
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DISCUSSION 
 
The recent unexpected findings in the FXII deficient mouse model have 
created a growing interest for more in vivo studies concerning the role of FXII in 
thrombosis.  Our experiments also have shown unexpected findings in a different 
species, adding more intrigue to this “elusive” protease.  The FXII deficient cats are 
able to form stable occlusive thrombi in veins at the same rate as normals on first 
injury.  Since we were not able to measure blood flow in the adjacent artery, little can 
be concluded about the role of FXII in arterial thrombosis in the cat.  However 
personal observations and unpublished data using the Folt’s model of carotid artery 
injury and measuring blood flow hemodynamics indicate that FXII deficient cats are 
able to form occlusive thrombi at nearly the same rate as normal cats.  The exciting 
new observation we report is that FXII deficient animals are significantly impaired in 
being able to form stable occlusive thrombi upon a second venous injury 48 hours 
later.  The significance of this finding may have impact on therapeutic strategies and 
monitoring of patients after repeated intravenous catheterization procedures or other 
vascular surgery procedures.  We attempted to find the reason(s) for the hemostatic 
difference by evaluating different factors important to thrombosis and fibrinolysis.  Is 
the delay in thrombus formation and inability to fully occlude on Day 3 due to a lack 
of thrombin generation or the presence of more profibrinolytic agents?  Our findings 
indicate that thrombin levels on Day 3 are not significantly different, albeit they are 
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reduced compared to normal cats.  It is possible that the slightly lower thrombin 
levels in FXII deficient cats contribute to their thrombotic change.  The significant 
finding (reduction) in the 30 minute cephalic samples may be due to sampling 
techniques since the cephalic vein can be difficult to access during surgery.  To 
answer the question concerning a profibrinolytic agent we looked at the fibrinolytic 
ability of plasma in euglobulin fractions and the presence of FDPs. Only a few 
animals had detectable fibrin degradation taking place, therefore rapid clot dissolution 
is not likely the explanation.  Further confirmation of this idea is given by the 
fibrinolytic ability assay.  The HZY cats had no significant changes in their ability to 
lyse a clot on Day 3 compared to Day 1.  In fact the NL cats had a steady decrease in 
fibrinolytic ability after injury on Day 3, however not a significant reduction. This 
could explain why the normal cats formed occlusions rather rapidly on Day 3 (Figure 
3.4).  Unfortunately we were not able to directly measure uPA and tPA activity in 
cats, but this data probably would not explain the lack of stable thrombus formation 
based on the other fibrinolytic indicators. 
Findings in the FXII-/- mice indicate platelet activation or some other FXII-
dependent interactions may be responsible for impaired thrombus formation in carotid 
arteries.35 Thrombus formation in arteries is more dependent on platelet activation by 
high shear force mechanisms than in veins.  However femoral veins are large vessels 
having higher flow velocities therefore platelets may be a factor in explaining our 
model differences.  One interaction that may be important and involves FXII is the 
binding of platelets and fibrin to neutrophils.   Factor XII can bind fibrin strands on 
neutrophils and dramatically enhance fibrin deposition in a developing thrombus.74 
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Neutrophils can provide a source of tissue factor in the growing thrombus.  
Upregulation of P-selectin by endothelial cells and neutrophils aids in leukocyte 
tethering to the endothelial cells and promotes thrombus formation by attracting 
microparticles (a source of TF) to the area of stasis.37  Platelets are also critical to 
thrombus initiation and helping to generate the “burst” of thrombin at the site of 
injury.  The interaction of FXII and platelets at the endothelial surface appears to be 
important in thrombin generation and subsequent thrombus formation in vivo.  Factor 
XII may co-localize with HK at the platelet glycoprotein Ibα receptor and regulate 
thrombin’s ability to activate platelets.78   
 In our study we looked at the role of FXII in inflammatory responses at 
the injury site.  We found FXII may promote leukocyte recruitment to the injured 
vein and effect MMP activation or expression.  Although systemic WBC counts did 
not indicate a difference between groups at 4 hours (Figure 3.5), a significantly higher 
number of leukocytes were present in the veins of NL animals (Table 3.3).  The 
inflammatory vascular response begins with a large influx of neutrophils/leukocytes 
from the vasa vasorum into the thrombus from about 2 to 48 hours after experimental 
injury in veins.118, 120, 151 Our data indicate that significantly fewer WBCs are present 
in FXII deficient animals at that high recruitment period (4 hours) in the veins. 
Previous studies agree with our findings and have confirmed that leukocytes in these 
FXII deficient cats can respond to chemotaxins normally.81 Since FXII can activate 
neutrophils and activate chemotactic agents, the lack of FXII most likely contributes 
to these mechanistic processes.   
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Factor XII can also activate proteolytic enzymes involved in matrix 
degradation.  Matrix metalloproteinase-1 can be activated by kallikrein (substrate of 
FXII) in a FXII-dependent manner.  The main role of MMP-1 is to cause the 
degradation of collagen, presumably to make leukocyte trafficking into the thrombus 
easier and to aid in capillary tube regression during healing.  Significantly increased 
levels of MMP-1 (has collagenase activity) and MMP-9 (has gelatinolytic activity) 
were seen in normal cats primarily in the veins after 48 hours.  The antibodies used in 
this study do not distinguish between activated and zymogen proteinase MMP-1 or -
9, therefore we cannot address the question of activity of enzymes present. In normal 
cats there was a significant increase in the total amount (intensity) of MMP-1 in their 
arteries at 48 hours which correlated with an increased WBC in the arteries.  
Neutrophils can activate MMPs by dumping proteolytic enzymes (elastase, cathepsin 
G, tryptase, chymase) from their primary granules into the matrix bed.96  Our findings 
agree with what is expected, i.e. increased numbers of leukocytes are associated with 
increased MMP activity.88,90-93  The loss of FXII activity would result in a loss of 
PMN influx, degranulation, and activation of MMP-1 and MMP-9.  The role of FXII 
appears to be significant at 48 hours.  Although no significant correlation was seen 
between FXIIa levels and MMP expression, an indirect relation through inflammatory 
modulation may be indicated.  More studies are needed to determine if there is any 
direct cause and effect of FXII on MMP activation in vivo, and outcomes of such 
mechanisms.  Neutrophils, monocytes, mast cells, eosinophils, and MMPs are 
extremely important in venous resolution. The finding of increased MMP-9 in our 
normal cat veins at 48 hours is in agreement with other studies.88 Kowalewski et al. 
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found MMP-1,-2 and -9 to be significantly increased in inflamed veins taken from 
human patients suffering from thrombophlebitis.151 This supports our finding that the 
NL cat veins have more inflammation (WBC/hpf), and higher expression of MMP-1 
and -9.  It is an interesting finding that vein matrix had more staining than arterial 
vessel matrix in NL cats.  This finding may indicate an increased level of matrix 
degradation in the smaller walled veins at that time point. A difference in MMP-1 and 
-9 activity in the vein versus artery (vein>artery) has been reported in humans.152 Our 
study was not designed to address issues of MMP activation or the role of FXII in 
thrombus resolution, however future studies are indicated by findings presented here.  
 The findings presented in this study indicate that FXII has a very 
important role in vascular thrombosis and its associated inflammatory responses in 
vivo.  Our data show a different thrombotic response in large veins and arteries than 
what the mouse model investigators report upon initial injury, however there is a 
similarity in a reduced thrombotic response at a proinflammatory phase (indicated by 
the significant increase in systemic WBCs and increased fibrinogen levels in all cats) 
at 48 hours.  The differences we show may reflect species differences or experimental 
design differences.  Activation of FXII is important in vivo and warrants further 
studies concerning pathological thrombi and platelet-leukocyte-endothelial cell 
interactions.
  
 
CHAPTER 4 
 
 
IN VIVO FXII RESPONSES INTRADERMAL INJURY 
 
TO HEME-INDUCED 
 
ABSTRACT 
 
Very little is known about the in vivo role of coagulation Factor XII or 
Hageman Factor in inflammation.   An inflammatory response is initiated during 
vascular injury in which neutrophils, monocytes, and platelets have been shown to 
play pivotal roles in thrombus attachment to the injured endothelium and recruiting 
new cells to the site to aid in the repair process.  Factor XII can activate neutrophils 
(PMNs) directly or indirectly via chemoattractants, however the magnitude of Factor 
XII’s cellular recruiting role is not known.  Our recent findings of reduced numbers 
of inflammatory cells at the site of vascular damage in Factor XII deficient cats 
sparked our interest in understanding FXII’s role in inflammatory responses related to 
blood cell degradation. We used free heme, a break-down product of hemoglobin and 
potent proinflammatory agent, to evaluate responses in FXII deficient cats.  Heme is 
plentiful in hemorrhagic tissues and induces neutrophil chemotaxis via G protein-
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coupled receptor activation.154  Factor XII has been shown to enhance leukocyte 
infiltrations into areas of immune-complex mediated (complement activation) 
inflammation.81  By injecting heme intradermally then retrieving tissues at 24 hours, 
we found a significant reduction in dermal leukocyte recruitment (peroxidase activity) 
in animals having less than 2% Factor XII activity compared to animals with normal 
(NL) factor XII.   Absolute leukocyte numbers were also reduced in FXII deficient 
animals. Vascular and dermal inflammatory responses after injury appear to be 
affected by Factor XII levels, suggesting Factor XII may be more important in 
inflammatory responses than coagulation.  
 
INTRODUCTION 
 
  A complex process of cell communication, migration and proliferation 
occurs when tissues or cells are injured.  The damaged cells signal for help from 
leukocytes, smooth muscle cells, and fibroblasts recruiting them to the injured area to 
aid in the containment of the “disaster” and repair of the damage.  If this injury 
disrupts the integrity of the vascular system, bleeding will need to be controlled and 
repair to the endothelium and underlying media and matrix components will need to 
be initiated. One particular initiator of this healing process is heme or heme proteins.  
Heme proteins are found in all cells, particularly in erythrocytes which carry large 
amounts of hemoglobin.  When freed from its protein, free heme has been shown to 
be a potent pro-inflammatory agent that can induce adhesion molecule expression, 
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increase vascular permeability, and act as a chemoattractant for leukocyte 
recruitment.154,155  Leakage of the vasculature results in blood entering the tissues 
where it becomes lysed, and allows the pro-oxidative free heme and heme proteins to 
be released.  Once released, the free heme signals inflammatory cells and induces 
oxidative stress that must be neutralized to prevent further damage.   Heme 
scavengers in the plasma such as albumin and hemopexin are normally present but 
they can be overwhelmed in large hemorrhages, leaving heme to accumulate in 
extravascular tissues.155   Thus large amounts of free heme can act as a beacon to alert 
the body to damage.  Degradation of free heme occurs by heme oxygenase (HO) 
enzymes which break down heme into biliverdin/bilirubin, iron, and carbon 
monoxide.154   The key to successfully repairing the damaged tissue lies in the body’s 
ability to mount an appropriate immune response involving many other blood and 
tissue components.   
Once injury and/or vascular permeability occur, the inflammatory process 
begins.  Endothelial cells retract, leaving small gaps between them, and they begin to 
express leukocyte adhesion markers.154 Leukocytes interact with the adhesion 
molecules (E-selectin, ICAM-1, VCAM-1) and become activated—further resulting 
in reactive oxygen species (ROS) and proteases.  The intracellular gaps are large 
enough to allow plasma proteins to enter the extracellular tissue while retaining blood 
cells in the vessel.154 Certain plasma proteins have been shown to have 
chemoattractant properties.  Zabel et al. showed serine proteases, coagulation factor 
twelve (FXII) and plasmin in particular, elastase and cathepsin G from neutrophils, 
along with mast cell tryptase had high chemerin activating abilities.  Chemerin is a 
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potent chemoattractant that triggers a rapid immune response via G-protein coupled 
receptor mediated chemotaxis.82   Others have shown FXII can induce chemotaxis of 
neutrophils (PMNs) directly through binding to the CD11b/18c receptor.74,75  Factor 
XII is critical in activating the kallikrein-kinin system (pro-inflammatory) and can do 
so without initiating coagulation in patients with an inflammatory disease, suggesting 
it may be important in inflammation regulation.34  
The question remains as to the significance of plasma coagulation proteins 
in the maintenance of inflammatory responses, whereas the importance of leukocytes 
in thrombus resolution has been known for years.   Neutrophils and their associated 
cytokines such as CXCL chemokines, IL-8, and IL-10 are important in venous 
thrombolysis86, and mast cells/monocytoid perivascular cells87,88 are important in 
vascular thrombosis and fibrinolysis.  In addition to thrombolysis, PMNs and mast 
cells can dump their proteolytic granules into the extra cellular tissue and activate 
matrix metalloproteinases (MMPs)—acting to digest collagen and elastin to aid in 
vessel remodeling.  It remains to be shown that FXII and kallikrein may be significant 
contributors to the vascular and tissue repair processes.    
We hypothesize that the continual breakdown of heme proteins occurring with 
thrombolysis of a clot or with hemorrhage provides an important initiating agent for 
localized inflammation.  However if FXII is not available to amplify this response, 
there may be a delay in resolving the thrombus and activating MMPs to aid in tissue 
repair and neointimal formation.  This could lead to a pathological thrombotic state 
and possibly delay wound healing. By studying the effects of heme-induced 
 105 
inflammation in the skin, we hope to clarify the extent of the in vivo role of FXII in 
this complex process. 
 
Materials and Methods: 
 
Animals 
Animal care was provided in accordance with the procedures outlined in the 
"Guide for Care and Use of Laboratory Animals" (National Research Council; 1996; 
National Academy Press; Washington, D.C.) and in accordance with a protocol 
approved by the Institutional Animal Care and Use Committee of the University of 
North Carolina at Chapel Hill.  Domestic breeder cats (Felis catus) were received 
from P. Bresnahan and limited in-breeding performed to maintain the line.  Animals 
were phenotyped for FXII activity (FXII:C) based on a modified APTT clotting assay 
as described by Kier et al.81and in Chapter 2.  Factor XII:C levels of <2% of a normal 
cat plasma pool defined cats as homozygote (HZY), <85% but >2% of a normal cat 
plasma pool as heterozygote (HET), and >85% as normal (NL).  The number of 
animals used for each group was 15 HZY, 6 HET, and 4 NL cats.  Two cats in each 
group under went the procedure twice in order to increase the sampling numbers.  
These cats were rested at least 2 months between procedures and received the 
inflammatory agent on the opposite flank at a location far from the first site. 
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Clinical Pathology:  All animals were screened for physical abnormalities 
and signs of disease.  White blood cell counts and skin evaluations were performed 
by the clinical veterinary staff and all cats were found to be within the normal range.  
Vaccinations were administered at a period greater than 6 months prior to the animal 
being used.  Animals were examined after the experimental procedure for any signs 
of abnormal wound healing (no abnormalities were detected in any of the groups). 
Inflammatory Agent (Heme) Preparation: 
  Heme or hemin was purchased from Frontier Scientific (Logan, UT) as a 
dry powder.  A stock solution was prepared with limited light exposure as 5 mg/ml in 
0.1M sodium hydroxide, vortexed for 5 minutes, pH adjusted to 7.50 with HCl, then 
filter sterilized into a sterile tube wrapped in foil.  Immediately before administering, 
the stock solution was diluted to a 300 microMolar concentration of heme in pyrogen-
free saline.  A vehicle control, pyrogen-free saline, was used on the opposite flank.   
Injection and Biopsy Procedure:   
Animals were sedated and gas anesthesia (1-3% isoflurane) was 
administered by mask for the short 15 minute procedures.  The skin was shaved of its 
hair and 70% alcohol was applied in a rubbing motion to remove surface 
contaminants.  On the first day (Day 1) the animals received 0.2 ml intradermally of 
300 µM heme on one flank and 0.2 ml of pyrogen-free saline on the opposite flank.  
Injection sites were circled with permanent marker for ease of retrieval 24 hours later.  
Twenty-four hours later (Day 2) animals were anesthetized and two 5 mm punch 
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biopsies were taken from each injection site (heme and saline): one punch biopsy 
sample was placed in a tube and immediately frozen in liquid nitrogen, the other 
sample was fixed in 10% neutral buffered saline for 48 hours before performing 
routine histology preparations.  The incision sites were closed with surgical glue and 
animals returned to their quarters.  Frozen biopsies were stored at -70˚C until further 
processing. 
Peroxidase Assay:   
This assay is a modification of an enzyme-substrate assay for the detection 
of peroxidases in skin samples as described by Ipaktchi et al.157. The basic principle 
of the reaction is as follows: Myeloperoxidase (MPO) and other hemoprotein 
peroxidases catalyze the hydrogen peroxide (H2O2)-dependent oxidation of halide 
ions and other organic compounds.  In its native form, MPO is in the ferric state 
(Fe3+) and can react with H2O2 to form a compound that can accept 2 electrons.  This 
reactive compound then oxidizes a halide such as Cl- or Br- which can combine with 
water (H2O) to form a hypohalous compound such as hypochlorous (HOCl-) that is a 
powerful anti-microbial.  The final step of this reaction is that the aromatic amine 
(ortho-dianisidine) is oxidized by the hypohalous acid and a color is produced.158 
Frozen tissue samples were thawed at room temperature, weighed, and homogenized 
with a Polytron (PT 1200 Kinematica AG) electric homogenizer in 2 ml of cold 
homogenization buffer consisting of 0.044 M monobasic potassium phosphate, 
0.0062 M dibasic potassium phosphate, 5 g/L hexadecyltrimethylammonium bromide 
(CTAB), and 0.001 M EDTA.   Skin is difficult to dismember therefore an additional 
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step of sonication was added using a Fisher Sonic Dismembranator Model 300 
(Fisher Scientific, USA).  Three cycles of homogenization then sonication for 10-15 
seconds, then rapid freeze-thawing were performed to each biopsy with care to add 
only 0.5 ml of homogenization buffer (to rinse the probe) per step.  A total volume of 
homogenization buffer at the end of tissue processing was 3.5 milliliters or adjusted 
to this volume before the peroxidase detection assay was performed.  Homogenates 
were centrifuged at 12,000 rcf for 30 minutes at 4˚C.  The supernatant was removed 
and stored at -70˚C until all samples could be analyzed as one batch.   
The supernatants were thawed and 20 µl added to a 96-well microtiter plate 
(run in duplicate).  Two hundred microliters of substrate buffer (made immediately 
before the experiment) was added to the well.  The substrate buffer consisted of 2.19 
ml of 1M monobasic potassium phosphate, 0.307 ml of 1M dibasic potassium 
phosphate, 4.15mg of ortho-dianisidine HCl, and 40.6 µl of 0.3% H2O2 adjusted with 
distilled water to a total volume of 25 milliliters.  A second substrate buffer was made 
containing the above reagents with 0.5 ml removed (to decrease the volume) and 0.5 
ml of 0.001M sodium azide in distilled water added.  This 10µM azide containing 
buffer was added to a separate well (run in duplicate also) on the same plate with 
another 20 µl of test subject’s supernatant (or homogenization buffer alone) in order 
to block non-myeloperoxidase activity (eosinophil peroxidase, catalase, heme, and 
lactoperoxidase mainly) that can react to the chromogenic substrate (ortho-
dianisidine).159  Azide inhibits heme proteins (myeloperoxidase included) but at a 10 
µM final concentration, it primarily blocks eosinophil peroxidase and lactoperoxidase  
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activities with only causing a 10% reduction in myeloperoxidase activity.159  The 
reaction was monitored every 30 seconds for optical density changes at 450 nm for 30 
minutes.  A lactoperoxidase (Calbiomed, CA) sample was used as a positive control 
for both ortho-dianisidine HCl and for checking the blocking ability of azide.  Sample 
values were subtracted from the corresponding azide-treated well then averaged. 
Peroxidase activity was expressed as ∆OD per minute per milligram tissue 
(∆OD/min/mg tissue).  This assay measures all peroxidases present.  The majority of 
peroxidases are released from neutrophils and eosinophils found in the skin tissues.  
Samples that had large amounts of activity not blocked by azide were repeated.  If 
they continued to show high activity, those samples were discarded since large 
amounts of heme interfering proteins were suspected.  Only two saline-injected 
homozygote cat samples were discarded, of note both cats had been previously 
injected with heme on that same side. 
Histological Processing and Evaluations:   
Skin biopsies were cut in half and oriented on their edge for sectioning in 
order to visualize all dermal layers with light microscopy.  Standard tissue processing, 
embedding, and sectioning were performed by a professional histopathology 
laboratory.  Serial sections were cut at 5µm each for 30 sections such that 2 sections 
per glass slide in serial order were collected (15 slides all together).  Four test animals 
were used to determine the number of sections necessary to be reviewed in order to 
find a depth of tissue that will show any inflammatory changes created and the 
consistency of section to section differences.  These test animal biopsies were serially 
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sectioned in full and stained with Mayer’s H&E.  Histological evaluations revealed 
that the first 6 slides (12 serial sections) provided a good estimation of the degree of 
inflammation therefore we chose to have experimental animals sectioned and stained 
for H&E (for leukocyte counting) in this manner.  Additional serial paraffin sections 
were taken for immunohistochemical analysis after the first 12 sections were taken. 
Inflammation scoring: 
 Two independent, trained reviewers (DAB and DEB) blinded to the animal 
treatment group counted and differentiated inflammatory cell types in 6 of the 12 
serial sections (ever other section) according to the following procedure.  (1) Each 
section was evaluated for the most inflamed region (indicated by the presence of 
leukocytes and tissue disruption) and the reviewer focused counting here. This biases 
the reviewer to an inflamed area.  (2) The most inflamed region was then subdivided 
into 4 fields (F): 
F1=epithelial/upper epidermis (papillary dermis) 
F2=layer of collagen fibers with hair shafts present 
F3=fatty hypodermis region of the dermis 
F4=muscle layer/lower hypodermis region of the dermis 
(3) At a 40x magnification, each reviewer counted/differentiated the number of 
eosinophils, neutrophils, and mononuclear cells found in one high power field (hpf) 
of each region.  A total of 24 counts (6 sections x 4 fields) were made for each cell 
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type. (4) Reviewer evaluations were compared for inter-rater reliability.  The highest 
number of inflammatory cells was found to be in F3 and F4. Neutrophil, macrophage, 
and eosinophil numbers in F3 and F4 in two animal’s left side biopsy sample were 
compared using a Spearman’s correlation coefficient.  The differential analyses 
(PMN, macrophage, eosinophils) did not correlate between reviewers.  Correlation 
was defined as having a >0.5 correlation coefficient.  However the total number of 
leukocytes counted in field 3 (F3) did correlate (coefficients of 0.5649 and 0.7201 for 
HZY and NL respectively) therefore only this field and total numbers were used for 
statistical purposes.  The reviewer data was averaged and the group means were 
compared using the Mann-Whitney U test since the samples were not normally 
distributed.  Only the HZY and NL groups were reviewed, the HET group was not 
reviewed.  The data is reported as means +/- 1 standard deviation (SD). 
Immunohistochemistry Staining:   
Immunohistochemical staining for matrix metalloproteinase-1 (MMP-1) and 
-9 (MMP-9), cathepsin G, and mast cell tryptase were performed as described in 
Chapter 3 with exceptions of antibody changes for cathepsin G and mast cell tryptase.  
Cathepsin G: sheep anti-human polyclonal purified antibody to cathepsin G protease 
was purchased from Abcam (Cambridge, MA) and reported to cross react to cat 
neutrophils160.  Blocking was done with normal horse serum and the primary antibody 
dilution was at 1:50.  Overnight incubation at 4˚C was performed before washing and 
adding the secondary antibody (Sigma Donkey anti-sheep HRP conjugated) as 
describe in Chapter 3.  The mouse anti-human monoclonal mast cell tryptase AA1 
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antibody was purchased from Thermo Fisher Scientific (Fremont, CA) and reported 
to cross react with feline protein according to the datasheet provided at a different 
supplier.161 The dilution of primary antibody used was 1:25 and incubation carried 
out at 4˚C overnight.  All other steps were the same as described in Chapter 3. 
Due to harsh conditions of antigen retrieval, the tissue specimens were lost 
or damaged to a point that would not allow reliable analysis.  The immuno-
histochemistry stained slides were not graded nor included in this study. 
 
RESULTS 
Heme induces a granulocytic response--The peroxidase assay measures the 
amount of peroxidases present in the skin biopsy tissue, generally a reflection of the 
number of granulocytic white blood cells (PMNs and eosinophils) present.  Our 
results revealed a significant reduction of (p=0.0499) in peroxidase activity in HZY 
animals compared to NL, but not with HET cats. Reduced peroxidase activity could 
mean fewer granulocytes are present but inflammation is the same (a 
monocytic/macrophagic response could be taking place in HZY cats instead).  
Therefore white blood cell differentials of the injury site are warranted in order to 
interpret this result as meaning “less inflammation”.  As expected the level of 
peroxidase activity in the saline injected tissues was significantly less (p=0.019) than 
heme-injected tissues and reflective of the nearly absent inflammation seen on H&E 
evaluation.  Figure 4.1 illustrates these differences in activity.  
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Figure 4.1: Peroxidase Activity of Cat Skin Biopsies After Injury 
“NL, HET, HZY Heme” indicates normal, heterozygote FXII deficient, and 
homozygote FXII deficient cats injected with heme, respectively. “NL, HET, 
HZY Saline” refers to tissues injected with saline. 
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 Factor XII deficient cats have fewer leukocytes at the site of injury--   
Normal cats had a larger inflammatory response (in all cell types) as indicated by the 
increased number of leukocytes per high power field present in one region of the skin.  
The difference between numbers of leukocytes in NL and HZY heme-injected tissues 
was approaching significance (p=0.073 with Mann-Whitney).  Unfortunately only 3 
NL cats had histological evaluations in the heme receiving tissues, making statistical 
analysis difficult.   The means and their variances in the total inflammatory cells 
 114 
counted per high power field for region (F3) in NL and HZY groups receiving heme- 
and saline-injections are shown in Table 4.1.  Increasing the numbers of NL animals 
being evaluated may bring significance to this finding. There was a significant 
difference between the heme-injected and saline-injected tissues of the normal cats 
(p=0.025) which indicates the heme did act as a proinflammatory agent.  There was 
no difference in the numbers of WBC per high power field in heme-injected and 
saline-injected sites of the FXII deficient cats, indicating either they did not mount a 
response to heme, or this method of enumerating has a high error rate.  No 
correlations were found with the peroxidase data, suggesting this method can help 
explain the peroxidase activity, however it should not be the sole means of measuring 
inflammatory responses.  An example of histological differences is given in Figure 
4.2, showing H&E sections of heme-injected skin for one normal and one 
homozygote cat. 
Table 4.1:  Average Number of Inflammatory Cells (WBC) Per High Power 
Microscopic Field In Hypodermis 
 
“NL Heme” indicates a normal cat having received heme in that skin site.  “NL 
Saline” indicates a normal cat received saline in the injection site.  “HZY Heme” 
indicates a homozygote FXII deficient cat received heme in the injection site.  
“HZY Saline” indicates a homozygote FXII deficient cat received saline in the 
injection site. 
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WBC/hpf in 
F3 (Hypodermis)
Mean +/- SD n
NL Heme 94.5 +/- 96.1 3
NL Saline 6.5 +/- 5.2 5
HZY Heme 15.2 +/- 14.7 11
HZY Saline 14.5 +/- 24.2 4
p=0.073 NL heme vs HZY heme
p=0.025
 
 
 
Figure 4.2: Histology (H&E) Examples of Heme-Injected Cat Skin 
One normal (NL) and one homozygote (HZY) representative photomicrograph 
illustrates the general inflammatory response differences between the two groups 
after receiving a single intradermal heme injection.  The area of focus is a small 
venule or adipocyte surrounded by inflammatory cells (arrow indicates inflamed 
area) located in the hypodermis.  Magnifications are at 20x. 
  NL cat skin    HZY cat skin 
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DISCUSSION 
The results of this study offer new insights into the role of FXII in acute 
inflammatory responses to a naturally occurring chemotactic agent—heme derived 
from lysed blood cells.   Previous findings by others agree with our findings that 
severely FXII deficient individuals have reduced responses in pro-inflammatory 
situations.80,81  After injecting purified heme into the dermis of skin, an inflammatory 
response was seen in all animals as indicated by the peroxidase activity (Figure 4.1).   
The severely FXII deficient animals (HZY) have a significantly reduced granulocytic 
response compared to animals with approximately 50% or more of normal levels of 
FXII. This finding was confirmed by semi-quantitative histological analyses 
indicating a pan-cellular response (with predominately granulocytic lineage) was 
diminished in HZY animals.  
 Careful evaluation of the HZY peroxidase activity reveals these animals did 
mount a significant (p<0.0001) response because their average heme-injected 
peroxidase values (0.9 +/- 0.2 ) are higher than their saline-injected values (0.2 +/-
0.1).  This particular assay is based on the utilizing a redox reaction in which other 
contaminating heme proteins or peroxidases could be a source of falsely elevated 
oxidizing agents.  We took precautions in limiting the effects of other peroxidases159, 
however there could be differences related to these.  Most likely the increase in 
peroxidase activity reflects the influx of leukocytes to the injury site and their 
subsequent dumping of myeloperoxidase into the tissues.  This is supported by our 
findings (Table 4.1) of increased numbers of WBCs per high power field in cats 
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having high peroxidase activity (this is an observation and not based on statistical 
analysis which showed no correlation). 
Unfortunately we were not able to identify any mechanism(s) that could 
help explain the reduced response.  Studies of neutrophil chemotactic responses to 
purified heme using human and mouse neutrophils show heme induces the protein 
kinase C (PKC) signalling pathway and other pathways by stimulating seven 
transmembrane receptors coupled to Gαi protein.154 Since there appeared to be a 
general reduction in all cell numbers in FXII deficients, not just the PMNs, the 
mechanism may be more broad.  The major WBC type found acutely after ischemia-
reperfusion and vascular injury is the PMN.88,153,154,162  Neutrophils are more 
prevalent in the circulation (40-60% of the WBC population) and can rapidly increase 
in numbers (neutrophilia) upon a sudden stress to the body, lending to their 
prevalence at injury sites.  Free heme enhances the inflammatory response156 and 
increases cell adhesion molecules on endothelial cells and vascular permeability154 
thereby making it easier for PMNs to respond.  We know FXIIa can bind PMN at 
their Mac-1 receptor74,75,77 and perhaps this mechanism is involved in heme-induced 
inflammatory responses. 
The information gained through our experiments with heme adds new 
knowledge to the role of FXII in acute inflammation driven by oxidative stress.  More 
investitgations are needed to identify the specific mechanisms associated with FXII 
and how it enhances leukocyte recruitment, especially in response to heme proteins.
  
 
CHAPTER 5 
 
FUTURE DIRECTIONS AND CLINICAL IMPLICATIONS 
 
The work presented in this dissertation has brought support and new 
questions to the importance of FXII in vivo.  We have shown that FXII in cats can 
significantly impact their ability to form stable thrombi during periods of acute 
inflammation.  But we don’t know why.  We have found that FXII enhances 
leukocyte recruitment to the site of injury, but is this related to free heme proteins or 
some other chemotactic factor(s) involved in mounting an inflammatory response?   
Does FXII impact the body’s ability to resolve venous thrombi?  Certainly it is 
expected to have some sort of an effect, perhaps a significant one, based on our 
findings.  It would be helpful to know if cytokines and MMPs are regulated 
differently in FXII deficient individuals after injury, and if a specific cell type, such 
as neutrophils, are responsible for any differences.   We also don’t know how the 
FXII protein interacts with its heavy chain structural domains during in vivo 
processes.  
The clinical implications of our findings are significant if the cat model 
translates to what happens in humans.  If patients are undergoing multiple surgeries or 
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intravascular procedures, FXII interactions may be a factor in how they are managed 
with anticoagulants or antithrombolytic agents.  Perhaps regulation of a local 
inflammatory response can be done through targeting FXII?  Of course this is tricky 
because FXII is involved in so many beneficial pathways that we may not want to 
alter.  A word of caution: drug targeting may not be effective since it appears FXII 
levels <2% of normal are needed to significantly impact inflammation at sites of 
injury.  The heterozygote cats (moderate FXII deficient animals) appear to act like 
normals in their thrombotic and inflammatory responses.  This brings even more 
questions for in vivo studies to pursue because we don’t know what minimal level is 
needed for FXII to impact the normal function of biological systems.   All these new 
possibilities and questions can be pursued with this animal model that is now better 
defined through our efforts presented here. 
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